SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

P4 - Poster Session IV

Event Time: Wednesday April 26, 2017 8:30 am to 7:00 pm
Topic(s): Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), General Neurology, Movement Disorders, MS and CNS Inflammatory Disease, Neuromuscular and Clinical Neurophysiology (EMG), Neuro-rehabilitation
Director(s):
Description: A series of thematic abstract presentations in poster format presented Sunday through Friday with evening stand-by times for authors. The specific stand-by time for this session is 5:30 pm to 7:00 pm.
Completion Message:
CME Credits: 0
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
11:45 AM - 11:50 AM P4.101 None  
11:50 AM - 11:55 AM P4.102 None  
11:55 AM - 12:00 PM P4.103 None  
12:00 PM - 12:05 PM P4.104 None  
12:05 PM - 12:10 PM P4.105 None  
12:10 PM - 12:15 PM P4.106 None  
12:15 PM - 12:20 PM P4.107 None  
12:20 PM - 12:25 PM P4.108 None  
12:25 PM - 12:30 PM P4.109 None  
12:30 PM - 12:35 PM P4.110 None  
5:30 PM - 7:00 PM Poster Author Standby Time None  

Disclosures

Speaker Disclosure

Abstract Presenters

Parkinson's Disease: Therapeutics and Telehealth II
Start Time Pub. Title Presenter
5:30 PM 001 Reliability of Continuous Parkinson’s Assessment Using Wearables Dustin Heldman, PhD
Disclosure:
Dr. Heldman has received personal compensation for activities with Great Lakes NeuroTechnologies Inc. as an employee.

5:30 PM 002 Exploring the use of wearable sensors to monitor drug response of patients with Parkinson’s disease in the home setting Jean-Francois Daneault
Disclosure:
Dr. Daneault has nothing to disclose.

5:30 PM 003 Telemedicine vs Office visits in a Movement Disorder Specialty Clinic: Comparative Satisfaction of physicians and patients. Ryan Hanson, MD
Disclosure:
Dr. Hanson has nothing to disclose.

5:30 PM 004 Telehealth Management of Parkinson’s Disease Using Wearable Sensors: An Exploratory Study Dustin Heldman, PhD
Disclosure:
Dr. Heldman has received personal compensation for activities with Great Lakes NeuroTechnologies Inc. as an employee.

5:30 PM 005 Virtual research visits in individuals with Parkinson disease enrolled in a clinical trial: REACT-PD Study Interim Analysis Christopher Tarolli, MD
Disclosure:
Dr. Tarolli has nothing to disclose.

5:30 PM 006 ND0701: A novel safe concentrated apomorphine formulation for continuous subcutaneous administration via a patch pump Ronit Shaltiel-Karyo
Disclosure:
Dr. Shaltiel-Karyo has received personal compensation for activities with NeuroDerm Ltd as an employee. Dr. Shaltiel-Karyo holds stock and/or stock options in Neuroderm.

5:30 PM 007 Fox Insight: a Large-Scale Web-Enabled Parkinson’s Disease Study Lana Chahine, MD
Disclosure:
Dr. Chahine has nothing to disclose.

5:30 PM 008 Improvements in activities of daily living and quality of life measures in Hoehn & Yahr subgroups of advanced Parkinson’s disease patients following treatment with IPX066, extended-release carbidopa-levodopa Rohit Dhall, MD
Disclosure:
Dr. Dhall has received personal Impax, Merz, Teva, Acadia, Medtronic, UCB, and IO Therapeutics as a speaker and/or consultant.

5:30 PM 009 Human factors testing of the levodopa-carbidopa intestinal gel delivery system in advanced Parkinson’s disease patients and healthcare providers Ramon L. Rodriguez
Disclosure:
Dr. Rodriguez has received personal compensation for activities with PeerView Institute for Medical Education, Merz, Lundbeck, Chelsea, AbbVie and the CME Meeting as a speaker. Dr. Rodriguez has received research support from Abbvie Inc., Allergan, Auspex, Biotie Therapeutics, Dystonia Coalition, Huntington Study Group, Ipsen, Merz Pharmaceuticals, National Parkinson Foundation, NIH/NINDS, Parkinson’s Study Group, and Chelsea.

5:30 PM 010 Optimizing Recruitment of Racial and Ethnic minority population in Clinical Trials in Parkinson's Disease: Potential Barriers and Prospective Strategies Pinky Agarwal
Disclosure:
Dr. Agarwal has received personal compensation for activities with US WorldMeds, Teva, ACADIA, Lunbeck, and Impax as a speaker and consultant. Dr. Agarwal has received research support from Pfizer Inc., Northwestern University, CDI Foundation, Merck & Co., Inc., US WorldMeds, Dystonia Coalition, Astellas, Adamas, Teva Pharmaceuticals, University of Rochester Medical Center Huntington Study Group, Partners Healthcare International, and Omeros.

Atypical Parkinsonism
Start Time Pub. Title Presenter
5:30 PM 011 Predictors of survival in progressive supranuclear palsy and multiple system atrophy - a systematic review and meta-analysis Stella Glasmacher
Disclosure:
Dr. Glasmacher has nothing to disclose.

5:30 PM 012 Pre- and post-synaptic dopaminergic dysfunction and clinical features in cerebellar type of multiple system atrophy Chaewon Lee
Disclosure:
Dr. Lee has nothing to disclose.

5:30 PM 013 Instrumented Gait and Balance Analyses in Progressive Supranuclear Palsy and Mild Cognitive Impairment compared with Parkinson Disease Trung Nguyen, MD
Disclosure:
Dr. Nguyen has research support from Eli Lilly & Company.

5:30 PM 014 Inflammatory pathology and rapidly progressive dementia contribute to the classic PSP phenotype Marian Dale, MD
Disclosure:
Dr. Dale has nothing to disclose.

5:30 PM 015 Correlation of Clinical and Neuroimaging Features in Progressive Supranuclear Palsy David French
Disclosure:
Dr. French has nothing to disclose.

5:30 PM 016 Whole-brain atrophy rates add a retrospective application to improve the diagnostic accuracy of multiple system atrophy and progressive supranuclear palsy vs idiopathic Parkinson's disease Carlos Guevara Oliva, MD
Disclosure:
Dr. Guevara Oliva has nothing to disclose.

5:30 PM 017 The identification of molecular-genetic background of familial atypical parkinsonism in "Hornacko", a specific region of the south-eastern Moravia, Czech Republic. Katerina Mensikova
Disclosure:
Dr. Mensikova has nothing to disclose.

5:30 PM 018 Patient Quality of Life and Caregiver Burden in a multidisciplinary MSA clinic Pravin Khemani
Disclosure:
Dr. Khemani has received personal compensation for activities with Lundbeck and Allergan as a member of the advisory board. Dr. Khemani has received research support from NINDS.

Parkinson's Disease: Functional and Structural Imaging
Start Time Pub. Title Presenter
5:30 PM 019 Subcortical Volumes differences among LRRK2, GBA and idiopathic Parkinson's disease patients and non-manifesting first-degree relatives Avner Thaler, MD
Disclosure:
Dr. Thaler has nothing to disclose.

5:30 PM 020 Comparative Analyses in Brain's MRI (Nigrosome and Neuromelanin) Versus 00mmTc-TRODAT-1 Spect in Movement Disorders Alex Baeta
Disclosure:
Dr. Baeta has nothing to disclose.

5:30 PM 021 White matter tract alterations in Parkinson’s disease patients with punding Francesca Imperiale
Disclosure:
Dr. Imperiale has nothing to disclose.

5:30 PM 022 Evolution in Dopamine Transporter (DaT) Scan Utilization Patterns and its Effect on Treatment Decisions: Results of the Next 200 Scans Xin Xin Yu
Disclosure:
Dr. Yu has nothing to disclose.

5:30 PM 023 Cortical tissue deterioration in PD: a longitudinal DTI study Richa Tripathi, MD
Disclosure:
Dr. Tripathi has nothing to disclose.

5:30 PM 024 A Retrospective Chart Review of Patients with Parkinsonism who underwent DaTSPECT Imaging to Distinguish Drug Induced Parkinsonism from Idiopathic Parkinson’s Disease Katherine Amodeo, MD
Disclosure:
Dr. Amodeo has nothing to disclose.

5:30 PM 025 Patient-Based Quantitative Analysis of DaT-SPECT uptake: Application in Patients with Parkinson and Asymptomatic Carriers of the G2019S LRRK2 Mutation Running title: Quantitative DaT in Parkinson’s disease Avner Thaler, MD
Disclosure:
Dr. Thaler has nothing to disclose.

5:30 PM 026 Autonomic Testing Profiles in Scans Without Evidence of Dopaminergic Deficit (SWEDD) Derek Stitt, MD
Disclosure:
Dr. Stitt has nothing to disclose.

5:30 PM 027 Dopaminergic neuronal oxidative stress is increased with disease progression in patients with Parkinson’s disease: A study with PET and SPECT Masamichi Ikawa
Disclosure:
Dr. Ikawa has nothing to disclose.

5:30 PM 028 White matter microstructural damage as predictor of cognitive decline in Parkinson’s disease Sebastiano Galantucci
Disclosure:
Dr. Galantucci has nothing to disclose.

5:30 PM 029 Diffusion tensor imaging changes in the corpus callosum and cognitive impairment in Parkinson's disease Ian Bledsoe, MD
Disclosure:
Dr. Bledsoe has received personal compensation for activities with Unum Insurance as a consultant.

5:30 PM 030 NA NA NA
Disclosure:

Neuro-rehabilitation: Motor Recovery and Spasticity Treatment
Start Time Pub. Title Presenter
5:30 PM 031 High-intensity interval ergometer training improves aerobic capacity and fatigue in patients with Multiple Sclerosis Stephan Schmidt, MD
Disclosure:
Dr. Schmidt has received personal compensation from Bayer Vital as a speaker. Dr. Schmidt has received research support from Bayer Vital.

5:30 PM 032 Effect of early use of AbobotulinumtoxinA (Dysport®) after stroke on spasticity progression: first results of a pilot study Raymond Rosales
Disclosure:
Dr. Rosales has received personal compensation for activities with Ipsen and Pfizer as a scientific advisory board member and consultant.

5:30 PM 033 Neuromuscular Electrostimulation (NMES) used for increasing quadriceps strength may also provide mild analgesia William Mays, MD
Disclosure:
Dr. Mays has nothing to disclose.

5:30 PM 034 The Adult Spasticity International Registry (ASPIRE) Study: 1-Year Results Gerard E. Francisco
Disclosure:
Dr. Francisco has received personal compensation for activities with Allergan, Ipsen, Mallinckrodt, and Merz. Dr. Francisco has received personal compensation in an editorial capacity for Journal of Rehabilitation Medicine. Dr. Francisco has received research support from Allergan, Ipsen, Mallinckrodt, Medtronic, Merz, Microtransponder, and Nexstim.

5:30 PM 035 Efficacy of IncobotulinumtoxinA in Treatment of Lower Limb Spasticity in Adults David Simpson, MD, FAAN
Disclosure:
Served as a consultant for Merz Pharmaceuticals GmbH, Allergan Inc and Ipsen Biopharm Ltd. Received research grant support from Merz Pharmaceuticals GmbH, Allergan Inc and Ipsen Biopharm Ltd.

5:30 PM 036 Duration of Treatment Effect of IncobotulinumtoxinA in Upper Limb Spasticity Bruce Rubin, MD
Disclosure:
Dr. Rubin has received personal compensation for activities with Allergan and Merz as a speaker and advisory board member.

5:30 PM 037 Efficacy of IncobotulinumtoxinA In The Treatment Of Shoulder Spasticity David Simpson, MD, FAAN
Disclosure:
Served as a consultant for Merz Pharmaceuticals GmbH, Allergan Inc and Ipsen Biopharm Ltd. Received research grant support from Merz Pharmaceuticals GmbH, Allergan Inc and Ipsen Biopharm Ltd.

5:30 PM 038 Duration of Effect of Abobotulinumtoxina (Dysport®) In Adult Patients with Upper Limb Spasticity (ULS) Post-Stroke or Traumatic Brain Injury Jean-Michel Gracies, MD
Disclosure:
J-MG is an investigator on an Ipsen trial.

5:30 PM 039 Effect of Rhythmic Auditory Stimulation On Gait In Patients With Stroke Mohamed Ahmed Ibrahim
Disclosure:
Dr. Ibrahim has nothing to disclose.

5:30 PM 040 The Effect of SSRIs in the Outcomes of ICARE Trial Samir Belagaje, MD
Disclosure:
Dr. Belagaje has nothing to disclose.

General Neurology: Myelopathies, ALS and Peripheral Nerve
Start Time Pub. Title Presenter
5:30 PM 041 Diffusion-Tensor-Imaging MR-Neurography for the detection of polyneuropathy in Type 1 diabetes Michael Vaeggemose
Disclosure:
My research is funded by the UNIK partnership foundation, Siemens A/G Copenhagen, the Danish Diabetes Academy supported by the Novo Nordisk Foundation and Aarhus University. .

5:30 PM 042 Diffusion Tensor Imaging of Peripheral Nerves in Patients with CMT Type 1A Michael Vaeggemose
Disclosure:
My research is funded by the UNIK partnership foundation, Siemens A/G Copenhagen, the Danish Diabetes Academy supported by the Novo Nordisk Foundation and Aarhus University. .

5:30 PM 043 A case of peripheral neuropathy due to pyridoxine toxicity in association with NOS energy drink consumption Kaitlyn Blackburn
Disclosure:
Dr. Blackburn has nothing to disclose.

5:30 PM 044 Incomplete spinal cord lesions: probably the commonest cause of radicular syndromes but difficult to diagnose Paul Teychenne
Disclosure:
Dr. Teychenne has nothing to disclose.

5:30 PM 045 Bilateral sural neuropathy during pregnancy: A case report Derek Y. Yuan, MD
Disclosure:
Dr. Yuan has nothing to disclose.

5:30 PM 046 Quantitative and qualitative normative dataset for intraepidermal nerve fibers at distal leg Jerome De Seze
Disclosure:
Dr. De Seze has received personal compensation for activities with Merck, Biogen, Novartis, Roche, Teva, LFB, Alexion, and Sanofi Genzyme. Dr. De Seze has received research support from LFB and Novartis.

5:30 PM 047 Hypothyroidism Presenting with Dysarthria and Intermittent Weakness of the Extremities Alicia Parker, MD
Disclosure:
Dr. Parker has nothing to disclose.

5:30 PM 048 Clinico-radiological spectrum of intranasal heroin myelopathy: a case series Alina Masters-Israilov, MD
Disclosure:
Dr. Masters-Israilov has nothing to disclose.

5:30 PM 049 Imaging of Acute Quadriparesis from Spinal Epidural Induced Pneumorrhachis David Carter
Disclosure:
Dr. Carter has nothing to disclose.

5:30 PM 050 Prevalence and treatment options for diabetic neuropathic pain in Kuwait. Samar Farouk Ahmed, MD
Disclosure:
Dr. Ahmed has nothing to disclose.

5:30 PM 051 Hypertrophic Cranial Polyneuropathies and Pituitary Lesions Ninad Desai, MBBS
Disclosure:
Dr. Desai has nothing to disclose.

5:30 PM 052 Eslicarbazepine Acetate in Neuralgic Pain Pino López Méndez
Disclosure:
Dr. Lopez Mendez has received personal compensation for activities with Bial as a speaker.

5:30 PM 053 Recurrent postpartum bilateral bell's palsy Tanaporn Rasameesoraj, MD
Disclosure:
Dr. Rasameesoraj has nothing to disclose.

5:30 PM 054 Bilateral Bell's Palsy Associated with Vogt-Koyanagi-Harada Disease : A Case Report George Lai
Disclosure:
Dr. Lai has nothing to disclose.

5:30 PM 055 Data-driven modelling of diffusion MRI changes in ALS indicates evolution of distal prior to proximal corticospinal tract pathology Matt C. Gabel
Disclosure:
Dr. Gabel has nothing to disclose.

5:30 PM 056 Takotsubo syndrome complicated with amyotrophic lateral sclerosis Yuishin Izumi
Disclosure:
Dr. Izumi has nothing to disclose.

5:30 PM 057 Tissue-engineered skin model derived from neurofibromatosis type 1 (NF1) patients to study tumor genesis and to predict response to therapy Vincent Roy, MSc
Disclosure:
Dr. Roy has nothing to disclose.

General Neurology: Vascular Neurology
Start Time Pub. Title Presenter
5:30 PM 058 Albumin neuroprotection in focal cerebral ischemia in humans: Another look at ALIAS trial subgroup Rakesh Khatri
Disclosure:
Dr. Khatri has nothing to disclose.

5:30 PM 059 Developmental Venous Anomalies in Neurological Disease: A Report of Six Cases Ahmed Z Obeidat, MD, PhD
Disclosure:
Dr. Obeidat has nothing to disclose.

5:30 PM 060 Intravascular T cell Lymphoma: A Rare, Poorly Characterized Entity with Cytotoxic Phenotype Tara Sharma, DO
Disclosure:
Dr. Sharma has nothing to disclose.

5:30 PM 061 Primary Angiitis of the Central Nervous System Bader Alenzi, MD
Disclosure:
Dr. Alenzi has nothing to disclose.

5:30 PM 062 Achieving better detection of vascular risk factors for stroke prevention Man Mohan Mehndiratta, MD, MBBS, FAAN
Disclosure:
Dr. Mehndiratta has nothing to disclose.

5:30 PM 063 Intraventricular bleed or foreign body? Nilofar Dudha
Disclosure:
Dr. Dudha has nothing to disclose.

5:30 PM 064 Ischemic stroke in a patient with Parry-Romberg syndrome Victoria Ebiana, MD
Disclosure:
Dr. Ebiana has nothing to disclose.

5:30 PM 065 Rapidly Progressive atypical Posterior Reversible Encephalopathy Syndrome (PRES) associated with B-cell lymphoma Yuri Bronstein, MD
Disclosure:
Dr. Bronstein has nothing to disclose.

5:30 PM 066 Case Report: Posterior reversible encephalopathy syndrome (PRES) associated with aseptic meningitis Qiang Zhang, MD, PhD
Disclosure:
Dr. Zhang has nothing to disclose.

5:30 PM 067 Hyperthermia induced posterior reversible encephalopathy syndrome: a rare presentation. Rafael Rodriguez, MD
Disclosure:
Dr. Rodriguez has nothing to disclose.

5:30 PM 068 A Proposed Mechanism for Hypobaric-induced Neuronal Injury: A Swine Model Philippine Dana Peralta, MD
Disclosure:
Dr. Peralta has nothing to disclose.

5:30 PM 069 VCAM_1 as a endothelial factor for diagnosis of dementia in Parkinson's disease Ali Ebrahimi
Disclosure:
Dr. Ebrahimi has nothing to disclose.

5:30 PM 070 NA NA NA
Disclosure:

Child Neurology and Epilepsy/Clinical Neurophysiology (EEG) ePoster Session
Start Time Pub. Title Presenter
5:30 PM 071 Automated Seizure Detection on the Median Power Spectrogram Using Computer Vision and Machine Learning Methods Peter Yan, MD
Disclosure:
Dr. Yan has nothing to disclose.

5:30 PM 072 PRES related reversible epileptic Anton’s syndrome Junaid Siddiqui, MD
Disclosure:
Dr. Siddiqui has nothing to disclose.

5:30 PM 073 Morphometric Analysis on T1-Weighted MRI Complements Visual MRI Review in Focal Cortical Dysplasia Alexandra Santana Almansa
Disclosure:
Dr. Santana Almansa has nothing to disclose.

5:30 PM 074 Postictal Clinical Features of Focal Dyscognitive Seizures David Harris
Disclosure:
Dr. Harris has nothing to disclose.

5:30 PM 075 Early epileptiform discharges as predictor of seizures in the pediatric intensive care unit Ryan Hodgeman
Disclosure:
Dr. Hodgeman has nothing to disclose.

5:30 PM 076 EEG findings in a Case of Congenital Zika Virus Syndrome Gurcharanjeet Kaur, MBBS
Disclosure:
Dr. Kaur has nothing to disclose.

5:30 PM 077 Efficacy of Cannabidiol in Children with Intractable Epilepsy Gurcharanjeet Kaur, MBBS
Disclosure:
Dr. Kaur has nothing to disclose.

5:30 PM 078 Further Delineation of Clinical Phenotype of Cerebellar Ataxia, Mental Retardation, and Disequilibrium Syndrome type 4 (CAMRQ4); Report of 5 New Patients and Review of Previously Reported Cases. Saud Alsahli
Disclosure:
Dr. Alsahli has nothing to disclose.

5:30 PM 079 SCALP/Schimmelpenning Syndrome (SNS) Presenting with Aneurysms and Neonatal Status Epilepticus Elizabeth Ng, MD, FAAP
Disclosure:
Dr. Ng has nothing to disclose.

5:30 PM 080 A novel pediatric presentation of epilepsy, nonanesthetic malignant hyperthermia, and congenital developmental delay associated with likely pathologic RYR1 variant. Anisha Schwarz, MD
Disclosure:
Dr. Schwarz has nothing to disclose.

Aging and Dementia: Cognitive and Neuropsychiatric Studies
Start Time Pub. Title Presenter
5:30 PM 081 Validity of DSM V Major Neurocognitive disorder criteria for population research in India Aashrai Gudlavalleti
Disclosure:
Dr. Gudlavalleti has nothing to disclose.

5:30 PM 082 Is Mini Mental State Examination the best test for lower educated individuals? Mariane de Moraes Monteiro
Disclosure:
Dr. de Moraes Monteiro has nothing to disclose.

5:30 PM 083 Neuropsychiatric Symptoms Related to Neuropathologic vs. Clinical Diagnosis of Dementia Letizia G. Borges, MD
Disclosure:
Dr. Borges has nothing to disclose.

5:30 PM 084 Neuropsychiatric symptoms in Latino patients with Alzheimer’s disease: an analysis of the NACC database Katya Rascovsky
Disclosure:
Dr. Rascovsky has nothing to disclose.

5:30 PM 085 Digital Self-Administered Gerocognitive Examination (eSAGE): Correlations with Neuropsychological Evaluations Douglas Scharre, MD
Disclosure:
Dr. Scharre has received personal compensation from Eli Lilly and BrainTest, Inc for consulting activities and serving on their scientific advisory board. Dr. Scharre has received royalty payments from BrainTest, Inc. for a licensed invention.. Dr. Scharre received research grants for clinical trial work from Axovant, Biogen, Lundbeck, Merck, Eli Lilly, AstraZeneca, BrainTest, AstraZeneca, Phylogeny, Avanir, Neurim, and Roche.

5:30 PM 086 Mining Data from Verbal Fluency Word Lists for Prediction of Amyloid Status David Clark, MD
Disclosure:
Dr. Clark has nothing to disclose.

5:30 PM 087 Measuring an Individual’s Degree of Semantic Impairment due to Temporal Pole Damage Carlos Roncero
Disclosure:
Dr. Roncero has nothing to disclose.

5:30 PM 088 Dementia & Amyloid Detection in Lewy Body Disorders Using The Philadelphia Brief Assessment of Cognition (PBAC) Amy Halpin
Disclosure:
Dr. Halpin has nothing to disclose.

5:30 PM 089 Clinical utility of memory measures in the differential diagnosis of mild cognitive impairment and major depressive disorder Bonnie Scott, MS
Disclosure:
Dr. Scott has nothing to disclose.

5:30 PM 090 A new treatment Paradigm for Neurodegeneration: Peroxidation-resistant polyunsaturated fatty acids (D-PUFA) lower brain amyloid beta and oxidation markers, and reverse cognition impairment in vivo Mikhail Shchepinov
Disclosure:
Dr. Shchepinov has received personal compensation for activities with Retrotope, Inc as an employee. Dr. Shchepinov holds stock and/or stock options in Retrotope Inc.

Aging and Dementia: Neuroimaging
Start Time Pub. Title Presenter
5:30 PM 091 Structural and functional brain connectome architecture in Alzheimer’s disease and amnesic mild cognitive impairment patients Massimo Filippi, MD
Disclosure:
Dr. Filippi has received compensation for consulting services and/or speaking activities from Biogen Idec, Excemed, Novartis, and Teva Pharmaceutical Industries. Serves on the scientific advisory board for Teva Pharmaceutical Industries.. Is Editor-in-Chief of the Journal of Neurology.. Receives research support from Biogen, Teva Pharmaceutical Industries, Novartis, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, Cure PSP, Alzheimer’s Drug Discovery Foundation (ADDF), the Jacques and Gloria Gossweiler Foundation (Switzerland), and ARiSLA (Fondazione Italiana di Ricerca per la SLA)..

5:30 PM 092 Common and differential patterns of brain atrophy in Alzheimer’s disease-related and non-related variants of posterior cortical atrophy Maxime Montembeault
Disclosure:
Dr. Montembeault has nothing to disclose.

5:30 PM 093 Advanced 1H-MRS detects decreased glutamate levels in amnestic MCI Burcu Zeydan
Disclosure:
Dr. Zeydan has nothing to disclose.

5:30 PM 094 ApoE-dependent differences in functional connectivity support memory performance in early-stage Alzheimer’s disease Matteo De Marco, PhD
Disclosure:
Dr. De Marco has nothing to disclose.

5:30 PM 095 Gait parameters as useful proxies in the early stage of Alzheimer’s disease: a Voxel Based Morphometry study Micaela Mitolo, PhD
Disclosure:
Dr. Mitolo has nothing to disclose.

5:30 PM 096 An efficient approach to obtain optimized metabolic PET and morphological MR data in dementia patients Kevin T. Chen
Disclosure:
Dr. Chen has nothing to disclose.

5:30 PM 097 Comparative Value of ASL-MRI and FDG-PET Imaging in Neurodegenerative Diseases: Cerebral Blood Flow vs. Glucose Metabolism Gustavo Roman, MD, FAAN
Disclosure:
Dr. Roman has nothing to disclose.

5:30 PM 098 Brain Atrophy in Early and Late Onset Alzheimer’s Disease and Suspected Non-Alzheimer’s Pathophysiology Eddie Stage
Disclosure:
Dr. Stage has nothing to disclose.

5:30 PM 099 Differences in brain metabolism in Early and Late Onset Alzheimer’s Disease and Suspected Non-Alzheimer’s Pathophysiology Victor Hugo Canela
Disclosure:
Dr. Canela has nothing to disclose.

5:30 PM 100 The synergistic interaction between amyloid and tau PET in the brain’s default mode network determines the clinical status in early Alzheimer’s disease. Tharick A. Pascoal
Disclosure:
Dr. Pascoal has nothing to disclose.

Epilepsy/Clinical Neurophysiology (EEG) Poster Discussion Session
Start Time Pub. Title Presenter
5:30 PM 101 The Association of Uncontrolled Seizures with Health-Related Quality of Life by Age Group among Patients with Epilepsy Fulton Velez
Disclosure:
Dr. Velez has received personal compensation for activities with Sunovion as an employee.

5:30 PM 102 Temporal and spectral characteristics of dynamic functional connectivity between resting-state networks in temporal lobe epilepsy Sharon Chiang
Disclosure:
Dr. Chiang has nothing to disclose.

5:30 PM 103 Healthcare Resource Utilization Among Patients With Lennox-Gastaut Syndrome Treated With Clobazam J. Eric Pina-Garza, MD
Disclosure:
Dr. Pina-Garza has received personal compensation for activities with Eisai, Lundbeck LLC, Supernus, and UCB Pharma as a consultant and member of the speakers bureau.

5:30 PM 104 Healthcare Resource Utilization and Projected Long-Term Cost Savings Following Clobazam Initiation in Patients With Lennox-Gastaut Syndrome John M. Stern, MD, FAAN
Disclosure:
Dr. Stern has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, Eisai, Sunovion, Lundbeck, and Cyberonics.. Dr. Stern has received personal compensation in an editorial capacity for MedLink.

5:30 PM 105 Analysis of Changes in Plasma Sodium Levels and Related Treatment-Emergent Adverse Events During Short- and Long-Term Use of Eslicarbazepine Acetate as Adjunctive and Monotherapy Robert Wechsler, MD, PhD, FAAN
Disclosure:
Speaking: Eisai, Livanova, Lundbeck, Sunovion, UCB Consulting: Alexza, Eisai, Engage, Lundbeck, Sunovion, UCB, Upsher-Smith.

5:30 PM 106 Etiologies and developmental outcomes in infants with new onset epilepsy: report of 40 consecutive patients Sandra Reiter-Campeau
Disclosure:
Dr. Reiter-Campeau has nothing to disclose.

5:30 PM 107 Long-term Postoperative Outcomes in Patients with Focal Cortical Dysplasia: Predictive Factors and AED Withdrawal Pue Farooque, DO
Disclosure:
Dr. Stanford has nothing to disclose.

5:30 PM 108 A dose ranging safety and pharmacokinetic study of cannabidol (CBD) in children with Dravet syndrome (GWPCARE1) Anup Patel, MD
Disclosure:
GW Pharmaceuticals and Liva Nova - Consulting Supernus - Scientific Advisory Board UCB Pharma - Scientific advisory board . GW Pharmaceuticals - Research Grant Upsher Smith - Research Grant Pediatric Epilepsy Research Foundation - Research Grant Brain Sentinel - Research Grant .

5:30 PM 109 A review of the drug–drug interactions of the new antiepileptic drug brivaracetam Brian Moseley, MD
Disclosure:
Dr. Moseley has received personal compensation for activities with UCB Pharma, Validus Pharmaceuticals, Eisai, and LivaNova. Dr. Moseley has received research support from Nonin Medical Inc.

5:30 PM 110 Randomized double-blind non-inferiority trial of lacosamide versus controlled-release carbamazepine monotherapy - subgroup analysis of unclassified patients with initial generalized tonic-clonic seizures only Konrad Werhahn
Disclosure:
Dr. Werhahn has received personal compensation for activities with UCB Pharma. Dr. Werhahn holds stock and/or stock options in UCB Pharma.

Neuromuscular and Clinical Neurophysiology (EMG): Motor Neuron Disease II
Start Time Pub. Title Presenter
5:30 PM 111 Mutational analysis of CCNF in ALS patients in Taiwan Yi-Chung Lee, MD
Disclosure:
Dr. Lee has nothing to disclose.

5:30 PM 112 Role of MicroRNA in Amyotrophic Lateral Sclerosis:evidence for gender and age of onset difference Valentina Pegoraro
Disclosure:
Dr. Pegoraro has nothing to disclose.

5:30 PM 113 Motor unit number estimation recording from the tongue: a pilot study Courtney McIlduff, MD
Disclosure:
Dr. McIlduff has nothing to disclose.

5:30 PM 114 An approach for optimizing muscle assessment with surface electrode array configurations used in electrical impedance myography Benjamin Sanchez, PhD
Disclosure:
Dr. Sanchez has nothing to disclose.

5:30 PM 115 Development of Biomarkers for the Diagnosis of Amyotrophic Lateral Sclerosis Scott Lewis
Disclosure:
Dr. Lewis has nothing to disclose.

5:30 PM 116 Edaravone (MCI-186) for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Assessment of the 40-Item ALS Assessment Questionnaire (ALSAQ-40) by Domain Koji Takei
Disclosure:
Dr. Takei has received personal compensation for activities with Mitsubishi Tanabe as an employee.

5:30 PM 117 Electrical Impedance Myography as a Surrogate Measure of Myofiber Size Jia Li
Disclosure:
Dr. Li has nothing to disclose.

5:30 PM 118 Generational Variance in Phenotypic Expression of Autosomal Dominant Spinal Muscular Atrophy Due to BICD2 Mutation Evan Jameyfield
Disclosure:
Dr. Jameyfield has nothing to disclose.

5:30 PM 119 Use of Big Data Analytics for Early Diagnosis of Amyotrophic Lateral Sclerosis (ALS) Tara Grawbowsky
Disclosure:
Dr. Grawbowsky has received personal compensation for activities with Vencore, Inc. as an employee.

5:30 PM 120 Counting the uncounted costs of Spinal muscular atrophy Michelle Farrar
Disclosure:
Dr. Farrar has nothing to disclose.

5:30 PM 121 Evaluation of Cognitive Reserve in Amyotrophic lateral Sclerosis MARCELO FRANCISCO RUGIERO
Disclosure:
Dr. RUGIERO has nothing to disclose.

5:30 PM 123 Axonal RNA Profiling of Human Motor Neurons as a Novel Approach to Study Axonopathies Mario Saporta, MD, PhD, FAAN
Disclosure:
Dr. Saporta has nothing to disclose.

5:30 PM 124 EEG Measures of Altered Cortico-Cortical Connectivity Correlate with Structural MRI Changes in Amyotrophic Lateral Sclerosis Bahman Nasseroleslami
Disclosure:
Dr. Nasseroleslami has nothing to disclose.

5:30 PM 125 Subjective perception of health in ALS: A moving target? Nimish Thakore, MD
Disclosure:
Dr. Thakore has nothing to disclose.

5:30 PM 126 Differentiating Flail Limb Syndrome from Amyotrophic Lateral Sclerosis Jeffrey Kornitzer, MD
Disclosure:
Dr. Kornitzer has nothing to disclose.

5:30 PM 127 CLINICOSOCIAL FACTORS THAT INFLUENCE DIAGNOSTIC DELAY IN ALS Drew Young
Disclosure:
Dr. Young has nothing to disclose.

5:30 PM 128 Correlations of a novel strength-based endpoint for tracking disease progression in amyotrophic lateral sclerosis with quality of life and functioning outcomes Jennifer Petrillo
Disclosure:
Dr. Petrillo has received personal compensation for activities with Biogen as an employee. Dr. Petrillo holds stock in Biogen.

5:30 PM 129 Assessment of olfactory dysfunction as a potential biomarker in Amyotrophic Lateral Sclerosis Cristina Viguera
Disclosure:
Dr. Viguera has nothing to disclose.

5:30 PM 130 Predictors of Mortality in Patients with Amyotrophic Lateral Sclerosis Akanksha Sharma, MD
Disclosure:
Dr. Sharma has nothing to disclose.

5:30 PM 131 Effectiveness of automatic intratracheal suctioning system for amyotrophic lateral sclerosis patients with tracheostomy-invasive ventilation Kiyonobu Komai, MD
Disclosure:
Dr. Komai has nothing to disclose.

5:30 PM 132 Radiological "Snake Eyes" Sign Due to Anterior Epidural Spinal Cyst Mimicking Hirayama Disease Abdallah Hamdallah MD, MD
Disclosure:
Dr. hamdallah MD has nothing to disclose.

5:30 PM 133 Immune Mediators as Biomarker Candidates in Familial Amyotrophic Lateral Sclerosis Anupama Kumar, MBBS
Disclosure:
Dr. Kumar has nothing to disclose.

5:30 PM 134 Ultra-High Field Proton MR Spectroscopy in Amyotrophic Lateral Sclerosis Ian Cheong
Disclosure:
Dr. Cheong has nothing to disclose.

Neuromuscular and Clinical Neurophysiology (EMG): Peripheral Neuropathy I
Start Time Pub. Title Presenter
5:30 PM 135 Haemodialysis Alters Peripheral Nerve Morphology in End-stage Kidney Disease Adeniyi Borire, MD
Disclosure:
Dr. Borire has nothing to disclose.

5:30 PM 136 Prominent Distal demyelination is a feature of Zika-Associated Guillain Barre Syndrome Natalia Betances
Disclosure:
Dr. Betances has nothing to disclose.

5:30 PM 137 Identification of a Novel Immune Mediated Cause for Small Fiber Neuropathy Todd Levine, MD
Disclosure:
Dr. Levine has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Griffons, Alexion, Nufactor, Diplomat, Shire, Corinthian Reference Labs. Dr. Levine holds stock and/or stock options in Corinthian Reference Labs. Dr. Levine has received research support from Alnylam, Malinckrodt.

5:30 PM 138 Diffusion Tensor Imagine of the Brachial Plexus and Cervical Spinal Nerve Roots: Case Controls Study in CIDP Patients and Controls Eve Chanson
Disclosure:
Dr. Chanson has nothing to disclose.

5:30 PM 139 Long-term course of idiopathic small fiber neuropathy Walter Haupt
Disclosure:
Dr. Haupt has nothing to disclose.

5:30 PM 140 The evaluation of small fiber neuropathy: a survey of American Academy of Neurology members Sujata Thawani, MD
Disclosure:
Dr. Thawani has nothing to disclose.

5:30 PM 141 Effects of Plasmapheresis in Neuropathic Pain, Local Inflammatory Cytokines, and Skin-Wrinkling-Response in Patients with Painful Peripheral Neuropathies. Eduardo De Sousa, MD, FAAN
Disclosure:
Dr. De Sousa was the recipient of the inaugural 2012 Plasma Exchange Innovation Award from Terumo BCT. This grant supported the research to be presented in poster format at the AAN 2017 Meeting.

5:30 PM 142 Alternate resistance and endurance training improves muscle strength and aerobic capacity in patients with chronic inflammatory demyelinating polyneuropathy Lars Høj Markvardsen
Disclosure:
Dr. Markvardsen has received personal compensation for activities with Octapharma Pharmaceuticals as a speaker. Dr. Markvardsen has received research support from Octapharma Pharmaceuticals.

5:30 PM 143 NA NA NA
Disclosure:

5:30 PM 144 NA NA NA
Disclosure:

Child Neurology II
Start Time Pub. Title Presenter
5:30 PM 145 Case Report: A transverse spinal cord infarct in a 15 year old male following lumbar epidural catheter placement Daniel Savitt, MD
Disclosure:
Dr. Savitt has nothing to disclose.

5:30 PM 146 Readmissions within Pediatric Neurology: A Quality Improvement Initiative Involving Discharge Optimization Jamie Heath, MD
Disclosure:
Dr. Heath has nothing to disclose.

5:30 PM 147 Defining Hand Stereotypies in Rett Syndrome: A Movement Disorders Perspective Marisela Dy, MD
Disclosure:
Dr. Dy has nothing to disclose.

5:30 PM 148 The Muscular Dystrophy Association (MDA) U.S. Neuromuscular Disease (NMD) Registry: Initial Data on Patients with Spinal Muscular Atrophy (SMA) Cynthia C. Jones
Disclosure:
Dr. Jones has received personal compensation for activities withBiogen as an employee. Dr. Jones holds stock and/or stock options in Biogen.

5:30 PM 149 Pediatric Thrombectomy: Case Presentation and Standardizing the INR process. Ittai Bushlin, MD, PhD
Disclosure:
Dr. Bushlin has nothing to disclose.

5:30 PM 150 Fetal central nervous system malformations: a ten year review of prenatal consultations at a tertiary care center Sonika Agarwal, MD
Disclosure:
Dr. Agarwal has nothing to disclose.

5:30 PM 151 A ten year profile of plasmapheresis use in pediatric neurologic disorders at a tertiary care center Jake Keller
Disclosure:
Dr. Keller has nothing to disclose.

5:30 PM 152 Detection rate of chromosomal microarray genetic testing in patients with cerebral palsy Rena Vanzo
Disclosure:
Dr. Vanzo has received personal compensation for activities with Lineagen as an employee. Dr. Vanzo has stock and/or stock options with Lineagan. Dr. Vanzo has received research support from Lineagan.

5:30 PM 153 Electroencephalographic Spectral Power in Girls with Rett Syndrome Katherine Roche
Disclosure:
Dr. Roche has nothing to disclose.

5:30 PM 154 Prophylactic therapy of cyclic vomiting syndrome in children: comparison of amitriptyline, cyproheptadine, and topiramate Shervin Badihian
Disclosure:
Dr. Badihian has nothing to disclose.

5:30 PM 155 Neuropsychological Profiles in Pediatric Neuromyelitis Optica Spectrum Disorder Eliza Gordon-Lipkin, MD
Disclosure:
Dr. Gordon-Lipkin has nothing to disclose.

5:30 PM 156 Association Between Affective Symptoms and School Bullying Experiences in Adults with Autism Spectrum Disorders Bryan Woodruff, MD
Disclosure:
Dr. Woodruff has received research support from Genentech.

5:30 PM 157 D-DEMO, A Novel and Distinct Phenotype Caused by ATP1A3 Mutations Lyndsey Prange
Disclosure:
Dr. Abdelnour has nothing to disclose.

5:30 PM 158 Healthcare Resource Use in Patients with Diagnosis of Spinal Muscular Atrophy (SMA) in Optum™ U.S. Claims Database Megan Teynor
Disclosure:
Dr. Teynor has received personal compensation for activities with Biogen as an employee. Dr. Teynor holds stock/stock options in Biogen.

5:30 PM 159 Truven Health MarketScan commercial claims database for Juvenile Myasthenia Gravis (JMG) Saahith Pochiraju
Disclosure:
Dr. Pochiraju has nothing to disclose.

5:30 PM 160 Autism Spectrum Disorder in Cerebrotendinous Xanthomatosis. Bianca ML Stelten
Disclosure:
Dr. Stelten has nothing to disclose.

5:30 PM 161 Hypoperfusion, vascular pruning, and transient hemiparesis mimicking stroke in transient erythroblastopenia of childhood Christopher Calahan
Disclosure:
Dr. Calahan has nothing to disclose.

5:30 PM 162 Malformations of cortical development: a case series of prenatal neurologic consultations and outcomes Jake Keller
Disclosure:
Dr. Keller has nothing to disclose.

5:30 PM 163 A Pilot Study to Assess the Feasibility and Impact of a Home Exercise Program on Heart Rate and Heart Rate Variability in Children with Muscular Dystrophy Aaron S. Zelikovich
Disclosure:
Dr. Zelikovich has nothing to disclose.

5:30 PM 164 Diagnostic Challenges in Pediatric Onset Hereditary Spastic Paraparesis (HSP) Gyula Acsadi, MD
Disclosure:
Dr. Acsadi has received personal compensation for activities with Biogen, Genentech, and AveXis as a consultant.

5:30 PM 165 Disruptive Behavior Problems in Levetiracetam-Treated Youth with Epilepsy Michelle Lally, MD
Disclosure:
Dr. Lally has nothing to disclose.

5:30 PM 166 Acute Flaccid Myelitis (AFM): 4 cases in 4 weeks Rahul Sinha, MD
Disclosure:
Dr. Sinha has nothing to disclose.

5:30 PM 167 Decorticate posturing with unresponsiveness- expanding the spectrum of Anti-VGKC antibody mediated autoimmune encephalitis in pediatrics Daniel Reiff
Disclosure:
Dr. Reiff has nothing to disclose.

5:30 PM 168 Novel mutations in RMND1 presenting with dystonia and seizures Maria J Sanchez-Quintero
Disclosure:
Dr. Sanchez-Quintero has nothing to disclose.

5:30 PM 169 A Case of GLUT1 Deficiency Associated Episodic Ataxia Without Epilepsy Dmitry Tchapyjnikov, MD
Disclosure:
Dr. Tchapyjnikov has nothing to disclose.

5:30 PM 170 Severe auto-immune sensory-autonomic neuropathy in an adolescent Zeyad Aljuhni
Disclosure:
Dr. Aljuhni has nothing to disclose.

5:30 PM 171 Outcome Of Revascularization In Patients With ACTA2 Cerebral Vasculopathy Trishna Kantamneni, MBBS
Disclosure:
Dr. Kantamneni has nothing to disclose.

5:30 PM 172 Rasmussen’s Encephalitis Treated with Responsive Neurostimulation System Maite La Vega-Talbott
Disclosure:
Dr. La Vega-Talbott has nothing to disclose.

5:30 PM 173 Dysmorphology in the Human Medial Superior Olive after Environmental Exposure to Pollution Kaitlyn Blackburn
Disclosure:
Dr. Blackburn has nothing to disclose.

5:30 PM 174 Novel mutation of DARS2 gene leads to a rare and aggressive presentation of leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL) Geetanjali Rathore, MD
Disclosure:
Dr. Rathore has nothing to disclose.

5:30 PM 175 Acute Pediatric Ischemic Stroke Management: a window for opportunity? Jonathan Pace
Disclosure:
Dr. Pace has nothing to disclose.

5:30 PM 176 Rapid-Onset Dystonia Parkinsonism with a rare mutation. Rachit Patil
Disclosure:
Dr. Patil has nothing to disclose.

5:30 PM 177 Co-occurrence of pathogenic mutations in mutiple genes in 2 siblings with Brown-Vialetto-Van Laere Syndrome Type 2 phenotype. Kallol Set
Disclosure:
Dr. Set has nothing to disclose.

5:30 PM 178 Homozygous AMT mutation in a patient with neonatal onset nonketotic hyperglycinemia and hyperammonemia Jeffrey Kornitzer, MD
Disclosure:
Dr. Kornitzer has nothing to disclose.

5:30 PM 179 New Clinical Phenotype Caused by a Novel SLC6A1 Mutation with Marked Responsiveness to Zonisamide Ashley Helseth, MD, PhD
Disclosure:
Dr. Helseth has nothing to disclose.

5:30 PM 180 Challenges in prenatal and neonatal diagnosis of Cornelia de Lange Syndrome: a case study Michael Stanley
Disclosure:
Dr. Stanley has nothing to disclose.

5:30 PM 181 Delayed versus dysmyelination in Jacobsen Syndrome Henry Osso-Rivera, MD
Disclosure:
Dr. Osso-Rivera has nothing to disclose.

5:30 PM 182 Levodopa responsive chorea with TITF1 mutation in brain-lung-thyroid disease Vijeta Shukla, MD
Disclosure:
Dr. Shukla has nothing to disclose.

5:30 PM 183 Sturge-Weber Syndrome Type 3 in a 44 year old woman: A Case report & review of literature. Jessica Lowe
Disclosure:
Dr. Lowe has nothing to disclose.

Behavioral and Cognitive Neurology: Neurodegenerative Disorders
Start Time Pub. Title Presenter
5:30 PM 184 Impaired Recognition of Sadness in Face or Voice Correlates with Spouses' Perception of Empathy in Frontotemporal Dementia Lauren Phillips
Disclosure:
Dr. Phillips has nothing to disclose.

5:30 PM 185 Characterization of Primary Progressive Aphasia and Prediction of Naming Decline by Multi-Modality MRI Andreia Faria
Disclosure:
Dr. Faria has nothing to disclose.

5:30 PM 186 Intonation as a disease marker in behavioral variant Frontotemporal Degeneration Naomi Nevler
Disclosure:
Dr. Nevlar has nothing to disclose.

5:30 PM 187 Clinical characteristics of 32 patients with rapidly progressive dementia with Lewy bodies Claudia Chou
Disclosure:
Dr. Chou has nothing to disclose.

5:30 PM 189 Targeting Neurotoxic Tau Oligomers through Intravenous Immunoglobulin (IVIG) Antibodies for the Treatment of Alzheimer’s Disease Tasneem F. Hasan
Disclosure:
Dr. Hasan has nothing to disclose.

5:30 PM 190 A case of sporadic adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia presenting as fronto-temporal dementia Ye Hu, MD
Disclosure:
Dr. Hu has nothing to disclose.

5:30 PM 191 A Brief Dementia Screening Test in South Africa: Results from the Health and Aging Longitudinal Study of an INDEPTH community (HAALSI) Farrah Mateen, MD, PhD, FAAN
Disclosure:
Dr. Mateen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with ZoomRx.

5:30 PM 192 Utility of Recognition Discriminability Index to Predict Conversion From Mild Cognitive Impairment to Alzheimer's Disease in the Alzheimer’s Disease Neuroimaging Initiative Maria Julieta Russo, MD
Disclosure:
Dr. Russo has nothing to disclose.

5:30 PM 193 Reading difficulties in a cohort of Spanish-speaking patients with Primary Progressive Aphasia. Jordi A. Matias-Guiu
Disclosure:
Dr. Matias-Guiu has nothing to disclose.

5:30 PM 194 MCI subtypes are heterogeneous and preceded by different risk factors: A study on aMCI and naMCI incidence Andrea Zammit
Disclosure:
Dr. Zammit has nothing to disclose.

5:30 PM 195 Rivastigmine and citalopram treatment for Alzheimer’s disease in every day clinical praxis. krishna Prasad Pathak
Disclosure:
Dr. Pathak has nothing to disclose.

5:30 PM 196 Localization of primary progressive apraxia of speech using functional MRI - a case study Danielle Spengler, MD
Disclosure:
Dr. Spengler has nothing to disclose.

5:30 PM 197 The neural basis of indirect speech act comprehension: Evidence from behavioral variant frontotemporal degeneration Meghan Healey
Disclosure:
Dr. Healey has nothing to disclose.

5:30 PM 198 Late-Onset Wilson's disease, Dementia, Ekbom syndrome and whitte matter hyperintensities Paula Marques
Disclosure:
Dr. Marques has nothing to disclose.

5:30 PM 199 FDG-PET, Neuropsychiatric Symptoms and the Risk of Incident Mild Cognitive Impairment Janina Krell-Roesch, PhD
Disclosure:
Dr. Krell-Roesch has nothing to disclose.

5:30 PM 200 Influence of dopaminergic system on manipulospatial function in persons with mild dementia and mild cognitive impairment YUTAKA TANAKA
Disclosure:
Dr. TANAKA has nothing to disclose.

5:30 PM 201 Implications for Management of PET Amyloid Classification Technology (IMPACT) Norman L. Foster M.D.
Disclosure:
Dr. Foster has received personal compensation for activities with Piramal and Bristol-Myers Squibb as a consultant. Dr. Foster holds stock and/or stock options in Proactive Memory Services, Inc. Dr. Foster has received research support from GE Healthcare, the Center for Health Improvement, Northern California Institute of Research, and the Veterans Administration.

5:30 PM 202 Novel microRNA related to learning and memory in mouse brain IFang Wang
Disclosure:
Dr. Wang has nothing to disclose.

Behavioral and Cognitive Neurology: Language
Start Time Pub. Title Presenter
5:30 PM 203 Gesture Comprehension and Language in Young Children with Autism Spectrum Disorder Tracey Knaus, PhD
Disclosure:
Dr. Knaus has nothing to disclose.

5:30 PM 204 Asymmetric intrahemispheric connectivity between left dorsal frontal lobe and perisylvian language network Borna Bonakdarpour, MD, FAAN
Disclosure:
Dr. Bonakdarpour has nothing to disclose.

5:30 PM 205 Network Graph Theory Analysis of Semantic Fluency in Russian - English Bilinguals Supriya Mahajan, MD
Disclosure:
Dr. Mahajan has nothing to disclose.

5:30 PM 206 Transcranial Direct Current Stimulation in Post-Stroke Aphasia: The Impact of Baseline Severity and Task Specificity Catherine Norise
Disclosure:
Dr. Norise has nothing to disclose.

5:30 PM 207 Naming of objects and actions in Multiple Sclerosis Nicoletta Caputi
Disclosure:
Dr. Caputi has nothing to disclose.

5:30 PM 208 Meg Localization of Cortical Activity During Language Processing Utilizing MR-Focus and Coherence Source Imaging Andrew M. Biondo
Disclosure:

5:30 PM 209 Impaired Gesture-Language Integration in Adolescents with Autism Spectrum Disorder Tracey Knaus, PhD
Disclosure:
Dr. Knaus has nothing to disclose.

5:30 PM 210 Areas Critical for Accessing Semantics from Spoken Words Hinna Shahid
Disclosure:
Dr. Shahid has nothing to disclose.

5:30 PM 211 Overrepresentation of isolated verbal repetition deficits in aphasic males with stroke: A systematic literature review and meta-analysis Lucía Pertierra
Disclosure:
Dr. Pertierra has nothing to disclose.

5:30 PM 212 Neural Bases of Dysgraphia after Acute Stroke Aishwarya Shukla
Disclosure:
Dr. Shukla has nothing to disclose.

5:30 PM 213 Detecting language processing in traumatic disorders of consciousness: A stimulus-based EEG study Camille Chatelle
Disclosure:
Dr. Chatelle has nothing to disclose.

Neuro-rehabilitation: Mechanism of Recovery
Start Time Pub. Title Presenter
5:30 PM 214 Clinical and molecular effects of functional electrical stimulation /lower extremity training in Myotonic Dystrophy Paola Cudia
Disclosure:
Dr. Cudia has nothing to disclose.

5:30 PM 215 Correlations between Cerebral Vascular Reactivity Deficits and Brain Parenchymal Volumes after Chronic Moderate/Severe TBI Kelley Flesher
Disclosure:
Dr. Flesher has nothing to disclose.

5:30 PM 216 Effects of Intra-Arterial Delivery of Mesenchymal Stem Cells on Infarct Size and Neurological Outcome in Rat Middle Cerebral Artery Occlusion Model: A Systematic Review and Meta-analysis Kunakorn Atchaneeyasakul, MD
Disclosure:
Dr. Atchaneeyasakul has nothing to disclose.

5:30 PM 217 Revised Constraint-Induced Aphasia Therapy (CIAT II): Neuroscience Foundations Traced from Basic Laboratory Research to Increased Spontaneous Real-World Speech and Cerebral Cortical Structure Victor Mark, MD
Disclosure:
Dr. Mark has nothing to disclose.

5:30 PM 218 Neuromodulation by task-concurrent dual transcranial direct current stimulation over the motor cortex in subacute stroke Chih-Wei Tang
Disclosure:
Dr. Tang has nothing to disclose.

5:30 PM 219 Central Post Stroke Pain: A Systematic Review Jonathan Singer
Disclosure:
Dr. Singer has nothing to disclose.

5:30 PM 220 What is the Molecular Mechanism of WldS-Mediated Axon Protection? Jack Wang, MD, PhD
Disclosure:
Dr. Wang has nothing to disclose.

5:30 PM 221 NA NA NA
Disclosure:

5:30 PM 222 NA NA NA
Disclosure:

Epilepsy and Clinical Neurophysiology (EEG): Status Epilepticus
Start Time Pub. Title Presenter
5:30 PM 223 Inadequacy of Benzodiazepine dosing in Status Epilepticus patients admitted to Neurointensive Care Unit Wazim Mohamed, MD
Disclosure:
Dr. Mohamed has nothing to disclose.

5:30 PM 224 Treatment of Patients in Status Epilepticus: A Retrospective Chart Review Trenton Tollefson, MD
Disclosure:
Dr. Tollefson has nothing to disclose.

5:30 PM 225 Quality Improvement for the Management of Pediatric Patients with Status Epilepticus Dmitry Tchapyjnikov, MD
Disclosure:
Dr. Tchapyjnikov has nothing to disclose.

5:30 PM 226 Clinical predictors and outcomes of refractory status epilepticus in a large urban hospital. Bhrugav Raval
Disclosure:
Dr. Raval has nothing to disclose.

5:30 PM 227 Prolonged super-refractory status epilepticus with excellent seizure and functional outcome. Angelica Lee, DO
Disclosure:
Dr. Lee has nothing to disclose.

5:30 PM 228 Levetiracetam in Non-Convulsive Status Epilepticus Guido Vazquez
Disclosure:
Dr. Vazquez has nothing to disclose.

5:30 PM 230 Convulsive status epilepticus due to all the evoluative stages of neurocysticercosis: Clinical profile and outcomes Jagarlapudi Murthy, MD, FAAN
Disclosure:
Dr. Murthy has nothing to disclose.

5:30 PM 231 Is serum albumin level associated with mortality? Correlation between proteins levels with status epilepticus mortality scoring systems. Maria Pacha
Disclosure:
Dr. Pacha has nothing to disclose.

Epilepsy and Clinical Neurophysiology: Co-Morbidities
Start Time Pub. Title Presenter
5:30 PM 232 The Effects of Depression on Length of Stay and Discharge Disposition among Patients with Epilepsy Rabia Jamy, MD
Disclosure:
Dr. Jamy has nothing to disclose.

5:30 PM 233 Suicidality in epilepsy: NDDI-E scale validation in Argentina. Blas Couto
Disclosure:
Dr. Couto has nothing to disclose.

5:30 PM 234 Are depression and anxiety disorders in epilepsy associated with atrophy of mesial temporal structures? Carlos Millan, MD
Disclosure:
Dr. Millan, M.D. has nothing to disclose.

5:30 PM 235 Drug-Resistant Focal Epilepsy and Chronic Traumatic Encephalopathy: clinical evaluation and pathological findings Amy Jones, MD
Disclosure:
Dr. Jones has nothing to disclose.

5:30 PM 236 Vitamin D and bone mineral density in epilepsy patients James Bathe, MD
Disclosure:
Dr. Bathe has nothing to disclose.

5:30 PM 237 Do neurology residents need a curriculum for learning about psychogenic nonepileptic seizures? Barbara Dworetzky, MD
Disclosure:
Dr. Dworetzky has received personal compensation for activities with SleepMed as a consultant.

5:30 PM 238 Is a history of psychiatric illness in patients with epilepsy a risk factor for developing psychiatric adverse events on antiepileptic medications? Ai Sumida, MD
Disclosure:
Dr. Sumida has nothing to disclose.

5:30 PM 239 Cognitive Testing and Depression scores in Patients with Epilepsy in relationship to Vitamin D levels Matthew Heard
Disclosure:
Dr. Heard has nothing to disclose.

Epilepsy and Clinical Neurophysiology: Clinical Epilepsy III
Start Time Pub. Title Presenter
5:30 PM 240 Development and Validation of the Refractory Epilepsy Screening Tool for Lennox-Gastaut Syndrome (REST-LGS): Improving Detection of LGS Danielle Boyce
Disclosure:
Dr. Boyce has received personal compensation for activities with Lundbeck LLC and Mallinckrodt as a member of the speakers bureau or as a consultant.

5:30 PM 241 Motor phenotype differentiates adult patients with Dravet Syndrome from Lennox-Gastaut Syndrome Danah Aljaafari, MD
Disclosure:
Dr. Aljaafari has nothing to disclose.

5:30 PM 242 The controversy surrounding voltage-gated potassium channel (VGKC)-complex antibodies: Case and Discussion Jonathan Galli, MD
Disclosure:
Dr. Galli has nothing to disclose.

5:30 PM 243 Assessing the Role of the Hippocampus in Visual Naming Using Hippocampal Morphometry in Left Temporal Lobe Epilepsy Patrick Bauer, MD
Disclosure:
Dr. Bauer has nothing to disclose.

5:30 PM 244 Patient Experiences with Epilepsy Treatments: Thematic Review of the Qualitative Literature Samuel Lapalme-Remis, MD
Disclosure:
Dr. Lapalme-Remis has nothing to disclose.

5:30 PM 245 Clinical Center for the Lafora Epilepsy Cure Initiative (LECI): Clinical Trial Readiness for a Global Curative Drug Trial Viet-Huong V. Nguyen
Disclosure:
Dr. Nguyen has nothing to disclose.

5:30 PM 246 Patterns of Drug Resistant Epilepsy in A Cohort of Adult Epilepsy Patients Taha A-Hakam
Disclosure:
Dr. A-Hakam has nothing to disclose.

5:30 PM 247 Seizure intractibility in geriatric and non-geriatric adult patients Rohit Marawar, MD
Disclosure:
Dr. Marawar has nothing to disclose.

5:30 PM 248 Self-reported antiepileptic medication adherence of adult patients with epilepsy Fong Kit Tam
Disclosure:
Mr. Tam has nothing to disclose.

5:30 PM 249 Quantitative EEG Detects REM Sleep to Enhance Epileptogenic Zone Localization Marcus Ng, MD
Disclosure:
Dr. Ng has nothing to disclose.

5:30 PM 250 NA NA NA
Disclosure:

Acute and Diagnostic Imaging in Ischemic Stroke and TIA
Start Time Pub. Title Presenter
5:30 PM 251 Ultrasound Criteria for Assessment of Vertebral Artery Origins Cory Rice
Disclosure:
Dr. Rice has nothing to disclose.

5:30 PM 252 Retinal and Ophthalmic Artery Studies in Ischemic Stroke Patients Using Fundus Photography and Transcranial Doppler Methods Kiran Patil
Disclosure:
Dr. Patil has nothing to disclose.

5:30 PM 253 Cerebral blood flow and auto-regulation in acute TIA patients from a general hospital in Qatar Adham Musthak
Disclosure:
Dr. Musthak has nothing to disclose.

5:30 PM 254 Sigmoid Sinus Characteristics Correlate with Early Clinical and Imaging Surrogates in Anterior Circulation Ischemic Stroke Johann Sellner, MD
Disclosure:
Dr. Sellner has received personal compensation for activities with Bayer, Biogen Idec, Merck-Serono, Novartis, Genzyme, and Teva.

5:30 PM 255 Infarct location predicts outcome in distal MCA occlusions Muhib Khan, MD
Disclosure:
Dr. Khan has nothing to disclose.

5:30 PM 256 Factors Affecting Distal Hyperintense Vessel Sign, a Postulated Marker for Intracranial Collateral Circulation Tarun Girotra
Disclosure:
Dr. Girotra has nothing to disclose.

5:30 PM 257 Clinical and imaging characteristics of silent brain infarction and symptomatic stroke Khaled Albazli
Disclosure:
Dr. Albazli has nothing to disclose.

5:30 PM 258 Early cognitive decline in symptomatic carotid stenosis is related to plaque inflammation and concomitant intracranial stenosis Chi Hsien Tan
Disclosure:
Dr. Tan has nothing to disclose.

5:30 PM 259 Vasa Vasorum Enhancement on Computerized Tomographic Angiography Correlates with Symptomatic Patients with 50% to 70% Carotid Artery Stenosis Raffaella Pizzolato Umeton
Disclosure:
Dr. Pizzolato Umeton has nothing to disclose.

5:30 PM 260 Association between Increased Brachial-ankle Pulse Wave Velocity and Cerebral Perivascular Space Fei-Fei Zhai
Disclosure:
Dr. Zhai has nothing to disclose.

5:30 PM 261 Quick-brain MRI as first imaging modality to diagnose pediatric stroke Alison Christy
Disclosure:
Dr. Christy has nothing to disclose.

Thrombolysis and Acute Evaluation in Ischemic Stroke
Start Time Pub. Title Presenter
5:30 PM 262 Early Clinical Improvement in Central Retinal Artery Occlusion is Associated with Central Retinal Artery Recanalization Mohammed Alkuwaiti, MD
Disclosure:
Dr. Alkuwaiti has nothing to disclose.

5:30 PM 263 Safety Of IV Thrombolysis For Acute Ischemic Stroke Patients With Thrombocytopenia Haris Kamal, MD
Disclosure:
Dr. Kamal has nothing to disclose.

5:30 PM 264 Intravenous Thrombolysis for Acute Ischemic Stroke in Patients with Thrombocytopenia Ashkan Mowla, MD, FAAN
Disclosure:
Dr. Mowla has nothing to disclose.

5:30 PM 265 Minor Strokes with proximal large vessel occlusion in anterior circulation; is intravenous thrombolysis enough Haris Kamal, MD
Disclosure:
Dr. Kamal has nothing to disclose.

5:30 PM 266 Imaging predictors of hemorrhagic transformation following intravenous rt-PA treatment for acute ischemic stroke. Nudrat Tasneem, MBBS
Disclosure:
Dr. Tasneem has nothing to disclose.

5:30 PM 268 Patient is Taking Antiplatelet at home- Does This Increase the Risk of Post Intravenous Thrombolysis Intracranial Hemorrhage? Sandhya Mehla, MD
Disclosure:
Dr. Mehla has nothing to disclose.

5:30 PM 269 Impact of Vascular Risk factors on Hemorrhagic Transformation Following rt-PA Administration for Acute Ischemic Stroke Amir Shaban, MD
Disclosure:
Dr. Shaban has nothing to disclose.

5:30 PM 270 Collaborative Interventions Reduce Time-to-Thrombolysis for Acute Ischemic Stroke in an Urban, Public Hospital Zachary Threlkeld, MD
Disclosure:
Dr. Threlkeld has nothing to disclose.

5:30 PM 271 Intravenous Thrombolysis in Anticoagulated and Thrombocytopenic Ischemic Stroke Patients Does Not Increase the Risk of Intracerebral Hemorrhage Nobl Barazangi, MD, PhD
Disclosure:
Dr. Barazangi has nothing to disclose.

5:30 PM 272 Trends in Alteplase Utilization in Louisiana’s Level III Hospitals Digvijaya Navalkele, MD
Disclosure:
Dr. Navalkele has nothing to disclose.

5:30 PM 273 Delays in Door-to-Needle Time for Acute Ischemic Stroke in the Emergency Department: A Comprehensive Stroke Center Experience Ashkan Mowla, MD, FAAN
Disclosure:
Dr. Mowla has nothing to disclose.

5:30 PM 274 Characteristics of patients presenting within the first 6 hours compared to historical controls Abeer Khoja, MD
Disclosure:
Dr. Khoja has nothing to disclose.

5:30 PM 275 Intravenous Thrombolytic Treatment of Acute Ischemic Stroke in Patients Older and Younger than 80 Years: Experience From One Hospital Hernan Bayona, MD
Disclosure:
Dr. Bayona has nothing to disclose.

5:30 PM 276 Risk of Symptomatic Intracranial Hemorrhage and Clinical Outcome after Intravenous Thrombolysis in Posterior Circulation Stroke: Results from the SITS-EAST Registry Roman Herzig, MD, PhD
Disclosure:
Dr. Herzig received personal compensation from Boehringer Ingelheim for serving on a scientific advisory board.

5:30 PM 277 Intravenous Tissue Plasminogen Activator for Patients with Mild or Rapidly Improving Ischemic Strokes and Large Vessel Occlusions: Examining In-hospital Outcomes Jeffrey Wagner, MD
Disclosure:
Dr. Wagner has received personal compensation for activities with Genentech as a speaker.

5:30 PM 278 Time Trend Analysis of Intravenous Thrombolytic Delivery across the Academic Year: an Academic Tertiary Medical Center Experience Sandhya Mehla, MD
Disclosure:
Dr. Mehla has nothing to disclose.

5:30 PM 279 Hispanic patients have longer door-to-needle times independent of age, gender and stroke severity Jonathan Cauchi, MD
Disclosure:
Dr. Cauchi has nothing to disclose.

5:30 PM 280 Target Stroke Implementation: Best Practice Strategies Cut Thrombolysis Time to < 30 minutes in a 1,550 Bed Academic Urban County Hospital Erika Marulanda-Londoño, MD
Disclosure:
Dr. Marulanda-Londoño has nothing to disclose.

5:30 PM 281 Increasing utilization of tissue plasminogen activator in acute ischemic stroke with staff changes Mohammed Majeed, MD
Disclosure:
Dr. Majeed has nothing to disclose.

5:30 PM 282 Analysis of Diagnostic Accuracy, Workflow and Time to Treatment during In-house 'Stroke Codes' Jody Manners
Disclosure:
Dr. Manners has nothing to disclose.

5:30 PM 283 Rapidly improving neurological deficit of stroke; case series in Academic institute, KAUH, Jeddah abeer khoja
Disclosure:
Dr. Khoja has nothing to disclose.

5:30 PM 284 Barriers to thrombolysis in a tertiary care institute in eastern India Apratim Chatterjee, MD
Disclosure:
Dr. Chatterjee has nothing to disclose.

5:30 PM 285 Resident door to needle Analysis: A retrospective Chart rEview (RACE) Neil Patel, MD
Disclosure:
Dr. Patel has nothing to disclose.

5:30 PM 286 High values of baseline and 24-hour Mean Arterial Pressure are associated with lower chance of early neurological improvement in acute stroke patients treated with thrombolysis Svetlana Lorenzano, MD, PhD, MSc
Disclosure:
Dr. Lorenzano has nothing to disclose.

5:30 PM 287 Can admission Brain Natriuretic Peptide level predict outcome after intravenous thrombolysis in acute ischemic stroke? Harsh Gupta
Disclosure:
Dr. Gupta has nothing to disclose.

In-Hospital Stroke Care
Start Time Pub. Title Presenter
5:30 PM 288 Herniation despite Decompression Hemicraniectomy in Large Hemispherical Strokes Archana Hinduja, MD
Disclosure:
Dr. Hinduja has nothing to disclose.

5:30 PM 289 Outcome of large hemispheric infarction in very elderly patients treated with medical management only Sudhir Datar, MD
Disclosure:
Dr. Datar has nothing to disclose.

5:30 PM 290 Early Decompressive Hemicraniectomy for Malignant Middle Cerebral Artery Infarction: A single centre retrospective study Chandra Bharatendu
Disclosure:
Dr. Bharatendu has nothing to disclose.

5:30 PM 292 Seizure Incidence in Ischemic Stroke Patients Treated with and without tPA: A Single Center Study Vaishnavi Vaidyanathan
Disclosure:
Dr. Vaidyanathan has nothing to disclose.

5:30 PM 293 PULMONARY EMBOLISM IN ACUTE ISCHAEMIC STROKE Prasanna Venkatesan Eswaradass, MD
Disclosure:
Dr. Eswaradass has nothing to disclose.

5:30 PM 294 Early Carotid Revascularization Reduces Readmission for Recurrent Ischemic Stroke in Acute Ischemic Stroke Patients: Analysis of United States Nationwide Readmissions Database Saqib Chaudhry, MD
Disclosure:
Dr. Chaudhry has nothing to disclose.

5:30 PM 295 Is Transesophageal Echocardiogram Associated with Neurological Worsening after Ischemic Stroke? Kevin Attenhofer, MD
Disclosure:
Dr. Attenhofer has nothing to disclose.

5:30 PM 296 Recent Nationwide Trends in Transcranial Doppler Utilization During Acute Ischemic Stroke Hospitalizations Yumei Liu
Disclosure:
Dr. Liu has nothing to disclose.

5:30 PM 297 Association of splenic contraction and development of SIRS after acute ischemic stroke. Alicia Zha, MD
Disclosure:
Dr. Zha has nothing to disclose.

5:30 PM 298 Analysis of current clinical practice on initiation of anticoagulation in patients with acute ischemic stroke. Edgar Olivas, MD
Disclosure:
Dr. Olivas has nothing to disclose.

5:30 PM 299 Stroke versus non-stroke neurological complications after cardiac transplant Guido Vazquez
Disclosure:
Dr. Vazquez has nothing to disclose.

5:30 PM 300 Dysautonomia and symptoms aggravation in acute lacunar stroke Kyong Jin Shin, MD
Disclosure:
Dr. Shin has nothing to disclose.

5:30 PM 301 Stroke Associated Pneumonia: The University Hospitals-Cleveland Medical Center experience Hatim Attar, MD
Disclosure:
Dr. Attar has nothing to disclose.

Neuroepidemiology: Cerebrovascular Disease I
Start Time Pub. Title Presenter
5:30 PM 302 Probable rapid eye movement sleep behavior disorder and risk of stroke: a prospective study Chaoran Ma
Disclosure:
Dr. Ma has nothing to disclose.

5:30 PM 303 Blacks Have Higher Risk of 1-Year Recurrent Ischemic Stroke and Lower 30-day Case Mortality: An Analysis of White and Black Medicare Beneficiaries, 1999-2013 Karen Albright, DO, MPH
Disclosure:
Dr. Albright has nothing to disclose.

5:30 PM 304 Sex Differences in Intracerebral hemorrhage Severity and Mortality Sandro Marini, MD
Disclosure:
Dr. Marini has nothing to disclose.

5:30 PM 305 Intermediate-term rates of stroke following cardiac procedures: the Nationwide Readmissions Database Laura Stein, MD
Disclosure:
Dr. Stein has nothing to disclose.

5:30 PM 306 Self-perceived psychological stress and risk of all-cause mortality after stroke: the Mashhad Stroke Incidence Study (MSIS) Hamidreza Saber, MD
Disclosure:
Dr. Saber has nothing to disclose.

5:30 PM 307 Race/ethnic Disparities in the Time from Stroke Symptom Onset to Hospital Arrival among Stroke Patients Arriving by EMS in the Florida-Puerto Rico Stroke Registry Hannah Gardener, ScD
Disclosure:
Dr. Gardener has nothing to disclose.

Neuroepidemiology: Cerebrovascular Disease II
Start Time Pub. Title Presenter
5:30 PM 308 Recurrence rate of Ischemic stroke: A single center experience Fasl Goldanne Buenaflor
Disclosure:
Dr. Buenaflor has nothing to disclose.

5:30 PM 309 No association of moon phase with stroke occurrence Jori Ruuskanen
Disclosure:
Dr. Ruuskanen has received personal compensation for activities with Merck, Biogen, and UCB Pharma.

5:30 PM 310 Delayed Cerebral Ischemia Secondary to Arteriovenous Malformation Rupture Fawaz Al-Mufti, MD
Disclosure:
Dr. Al-Mufti has nothing to disclose.

5:30 PM 311 Obstructive Sleep Apnea is Associated with Improved Non-Traumatic Subarachnoid Hemorrhage Outcomes Dominique Low, MD
Disclosure:
Dr. Low has nothing to disclose.

5:30 PM 312 Obstructive Sleep Apnea is Associated with Improved Ischemic Stroke Outcomes Dominique Low, MD
Disclosure:
Dr. Low has nothing to disclose.

5:30 PM 313 Prevalence of spasticity in patients suffering from ischemic stroke in the internal carotid artery territory - the results of interim analysis of the national registry SONAR Petr Kanovský, PhD
Disclosure:
Dr. Kanovsky has received research support from Merz.

Neuroepidemiology: Neuromuscular & Multiple Sclerosis
Start Time Pub. Title Presenter
5:30 PM 314 Extrapyramidal involvement in ALS: a prospective population-based study Adriano Chio, MD, FAAN
Disclosure:
Dr. Chiò has received personal compensation for activities with Biogen, Cytokinetics, Neuraltus, Mitsubishi and Italfamaco.

5:30 PM 315 A Survival Model for US Patients Enrolled in the National ALS Registry Web Portal Theodore Larson
Disclosure:
Dr. Larson has nothing to disclose.

5:30 PM 316 From Snow to Hill to ALS: An odyssey in epidemiology Carmel Armon
Disclosure:
Dr. Armon has received personal compensation for activities with emedicine.com. Dr. Armon has received royalty payments from UpToDate.

5:30 PM 317 Validation and continuing development of a patient-reported survey of small-fiber polyneuropathy symptoms Gary Zirpoli
Disclosure:
Dr. Zirpoli has nothing to disclose.

5:30 PM 318 A stratified approach for mutational analysis delineates molecular epidemiology of early-onset SCD in the Japanese population Yuka Hama
Disclosure:
Dr. Hama has nothing to disclose.

5:30 PM 319 Hearding: a new phenomenon affecting medical decision-making in Multiple Sclerosis care? Gustavo Saposnik, MD
Disclosure:
the present study was supported by the Spanish Neurological Society and Roche Pharma. Dr. Saposnik, PI of the study (DISCUTIR MS) received NO personal compensation..

Neuroepidemiology: Movement Disorders & Dementia
Start Time Pub. Title Presenter
5:30 PM 320 Air Pollution and Risk of Parkinson’s Disease in a Large Prospective Study of Men. Natalia Palacios, PhD
Disclosure:
Dr. Palacios has nothing to disclose.

5:30 PM 321 Well-water and risk of Parkinson Disease: a case-control study of US Medicare beneficiaries Maya Silver
Disclosure:
Dr. Silver has nothing to disclose.

5:30 PM 322 Mild Traumatic Brain Injury Is Associated with Increased Risk of Parkinson Disease in Military Veterans: A Chronic Effects of Neurotrauma Consortium Study Raquel C. Gardner, MD
Disclosure:
Dr. Gardner has nothing to disclose.

5:30 PM 323 Huntington Disease in Russia: an Epidemiological Challenge? Yury Seliverstov
Disclosure:
Dr. Seliverstov has received personal compensation for activities with Teva Pharmaceuticals.

5:30 PM 324 High Prevalence of Mild Cognitive Impairment and Dementia in a social vulnerable population in Argentina: A starting point for dementia prevention. Maria Julieta Russo, MD
Disclosure:
Dr. Russo has nothing to disclose.

Neuroepidemiology
Start Time Pub. Title Presenter
5:30 PM 325 Gender Specific Outcomes and Predictors of Concussion Recovery: A Single Site 15-year Ivy League Experience Cecilia Davis-Hayes
Disclosure:
Dr. Davis-Hayes has nothing to disclose.

5:30 PM 326 U.S. Burden of Hospital Admissions and Utilization of Hospice Care for Patients with Malignant Brain Tumor Benjamin George, MD
Disclosure:
Dr. George has nothing to disclose.

5:30 PM 327 Prevalence of primary headache disorders in Kuwait: A national study. Jasem Y Al-Hashel, MD
Disclosure:
Dr. Al Hashel has nothing to disclose.

5:30 PM 328 Risk factors for developing epilepsy in a U.S. commercially insured pediatric population Ahyuda Oh
Disclosure:
Dr. Oh has nothing to disclose.

Cognitive Impairment in Multiple Sclerosis: Clinical and MRI Correlates
Start Time Pub. Title Presenter
5:30 PM 329 The Bayesian Risk Estimate at disease onset predicting early cognitive and physical disability in CIS and MS patients Marianne Said
Disclosure:
Dr. Said has nothing to disclose.

5:30 PM 330 Speeded Saccadic Eye Movement Predicts Symbol Digit Modalities Test Performance in Multiple Sclerosis Natali Baner
Disclosure:
Dr. Baner has nothing to disclose.

5:30 PM 331 Improved processing speed in multiple sclerosis during fingolimod therapy: oral Symbol Digit Modalities Test response in PREFERMS Ralph H.B. Benedict, PhD
Disclosure:
Dr. Benedict has received personal compensation for activities with Actelion, Biogen Idec, Bayer, and Novartis as a consultant.

5:30 PM 332 Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS) predicts performance on instrumental activities of daily living Michael Shaw
Disclosure:
Dr. Shaw has nothing to disclose.

5:30 PM 333 The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and Orientation Tests Francesco Saccà
Disclosure:
Dr. Sacca has received personal compensation activities with Novartis, Almirall, Genzyme, and TEVA a speaker, editorial work, and advisory boards.

5:30 PM 334 TVA - a new technique to detect early cognitive dysfunctions Wolfgang Koehler
Disclosure:
Dr. Koehler has received personal compensation for activities with Merck, Bayer, Biogen, Novartis, Genzyme and Sanofi.

5:30 PM 335 Telerehabilitation using Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) Enhances the Benefit of At-Home Cognitive Training in Multiple Sclerosis Bryan Dobbs
Disclosure:
Dr. Dobbs has nothing to disclose.

5:30 PM 336 Are cognitive deficits in MS related to cortical or whole brain atrophy - a chicken-and-egg problem? Wolfgang Koehler
Disclosure:
Dr. Koehler has received personal compensation for activities with Merck, Bayer, Biogen, Novartis, Genzyme and Sanofi.

5:30 PM 337 Multiple Sclerosis: Brain Atrophy and Computerized Cognitive Testing - A Longitudinal Investigation of Changes in Disease Impact Eric Greif
Disclosure:
Dr. Greif has nothing to disclose.

5:30 PM 338 Cognitive performance in radiologically isolated syndrome Anat Achiron, MD, PhD
Disclosure:
Dr. Achiron has received personal compensation for activities with Genzyme, Roche, Teva Pharmaceuticals, and Novartis as a scientific advisory board member and consultant. Dr. Achiron has received research support from Bayer-Schering Pharma, Biogen Idec, Teva Pharmaceutical Industries Ltd., Genzyme, Merck Serono, and Novartis.

5:30 PM 339 Thalamic functional connectivity in Multiple Sclerosis: the role of temporal thalamic sub-region in maladaptation Alessandro D'Ambrosio
Disclosure:
Dr. D'Ambrosio has nothing to disclose.

5:30 PM 340 Longitudinal Assessment of Large-Scale Brain Functional Networks in Patients with MS: Relationship with Clinical Disability and Cognitive Impairment Fiammetta Pirro
Disclosure:
Dr. Pirro has nothing to disclose.

5:30 PM 342 Maladaptive personality in multiple sclerosis and its relation to cognitive status Shumita Roy
Disclosure:
Dr. Roy has nothing to disclose.

5:30 PM 343 High conscientiousness is related to less thalamic and other subcortical gray matter atrophy in multiple sclerosis Tom Fuchs
Disclosure:
Dr. Fuchs has nothing to disclose.

5:30 PM 344 Attention and Processing Speed Performance in Multiple Sclerosis is Mostly Related to Thalamic Volume Alvino Bisecco
Disclosure:
Dr. Bisecco has nothing to disclose.

5:30 PM 345 Structural and Functional MRI Predictors of Disability and Cognitive Impairment Accrual in Patients with Multiple Sclerosis Fiammetta Pirro
Disclosure:
Dr. Pirro has nothing to disclose.

5:30 PM 346 Unique Within-Network Functional Connections Characterize Memory and Information Processing Speed in Multiple Sclerosis Victoria Leavitt, PhD
Disclosure:
Dr. Leavitt has nothing to disclose.

5:30 PM 347 Pittsburgh compound-B PET and MRI biomarkers of cognition in aging MS patients Burcu Zeydan
Disclosure:
Dr. Zeydan has nothing to disclose.

5:30 PM 348 Extending the Concept of Reserve from Cognitive to Physical Disability in Multiple Sclerosis James Sumowski
Disclosure:
Dr. Sumowski has nothing to disclose.

5:30 PM 349 Multiple Sclerosis: Brain Atrophy and Computerized Cognitive Testing - A Cross-Sectional Pilot Investigation Eric Greif
Disclosure:
Dr. Greif has nothing to disclose.

5:30 PM 350 Cerebral regions involved in executive dysfunctions in Multiple Sclerosis Panagiotis Bachoumas
Disclosure:
Dr. Bachoumas has nothing to disclose.

5:30 PM 351 Looking into cognitive impairment in primary-progressive MS Maria Petracca
Disclosure:
Dr. Petracca has nothing to disclose.

5:30 PM 352 Intra Individual Variability in Reaction Time Is Sensitive Across the Lifespan in Multiple Sclerosis William Pau
Disclosure:
Dr. Pau has nothing to disclose.

5:30 PM 353 Frontal structural connectivity is related to complex processing speed performance in relapsing-remitting multiple sclerosis. Riccardo Manca, Msc
Disclosure:
Dr. Manca has nothing to disclose.

Neuroimaging I: Lesions and Myelin Imaging in Multiple Sclerosis
Start Time Pub. Title Presenter
5:30 PM 354 MS lesions demonstrating a QSM hyperintense-rim have more myelin loss compared to those without a QSM hyperintense-rim Yihao Yao
Disclosure:
Dr. Yao has nothing to disclose.

5:30 PM 355 Performance Evaluation for Automated Lesion Segmentation Tool: Lesionquant Weidong Luo
Disclosure:
Dr. Luo has received personal compensation for activities with CorTechs Labs Inc. as an employee.

5:30 PM 356 Assessing T2 Lesion Stability Over Time in Multiple Sclerosis Devon Conway, MD
Disclosure:
Dr. Conway has received personal compensation for activities with Arena pharmaceuticals as a consultant. Dr. Conway has received research support from Novartis pharmaceuticals.

5:30 PM 357 Natural history of multiple sclerosis inflammatory brain lesions: a FLAIR and T1w post contrast MRI volumetric analysis Pietro Maggi, MD, PhD
Disclosure:
Dr. Maggi has nothing to disclose.

5:30 PM 358 Association of Quantitative MRI to Radiological Reporting for the Evaluation of Lesion Burden Status in Multiple Sclerosis: A Multi-Center Study Annemie Ribbens
Disclosure:
Dr. Ribbens has nothing to disclose.

5:30 PM 359 Individual profiles of cortical myelin repair predict neurological disability in multiple sclerosis: a combined PET-MT approach Benedetta Bodini
Disclosure:

5:30 PM 360 Inhomogeneous Magnetization Transfer (ihMT) in normal-appearing tissue correlates with disability of multiple sclerosis patients. Elise Van Obberghen
Disclosure:
Dr. Van Obberghen has nothing to disclose.

5:30 PM 361 Quantitative Magnetization Transfer Imagingof the Brain at 7.0 Tesla: Post Mortem Validation and in Vivo Application in Multiple Sclerosis Francesca Bagnato, MD
Disclosure:
Dr. Bagnato has nothing to disclose.

Neuroimaging II: Imaging Brain Gray matter and Spinal Cord in Multiple Sclerosis
Start Time Pub. Title Presenter
5:30 PM 362 The combined use of 3D T1- and T2-weighted sequences improves cervical cord lesion detection in patients with multiple sclerosis: a multicenter study at 3T Loredana Storelli
Disclosure:
Dr. Storelli has nothing to disclose.

5:30 PM 364 Subcortical gray matter atrophy is predicted by white matter lesions in directly connected tracts in multiple sclerosis Tom Fuchs
Disclosure:
Dr. Fuchs has nothing to disclose.

5:30 PM 365 In vivo characterization of grey and white matter spinal cord pathology in multiple sclerosis using ultra high field MRI Russell Ouellette
Disclosure:
Dr. Ouellette has nothing to disclose.

5:30 PM 366 A comprehensive assessment of cervical cord lesions in patients with multiple sclerosis on T1-MPRAGE at 3T: relationship with cord atrophy and disability Loredana Storelli
Disclosure:
Dr. Storelli has nothing to disclose.

5:30 PM 367 Structural connectivity in multiple sclerosis and simulation of disconnection Paolo Preziosa, MD
Disclosure:
Dr. Preziosa has received personal compensation for activities with Biogen Idec, Novartis and ExceMED as a speaker.

5:30 PM 368 Baseline hippocampal subfield volumes differ in CIS patients converting to clinically defined MS: a 1 year follow-up study Laura Cacciaguerra
Disclosure:
Dr. Cacciaguerra has nothing to disclose.

5:30 PM 369 Dynamic changes of hippocampal subfields in CIS patients: a 2-year MRI longitudinal study Laura Cacciaguerra
Disclosure:
Dr. Cacciaguerra has nothing to disclose.

5:30 PM 370 MRI Evidence of Acute Inflammation in Cortical Gray Matter of Early Multiple Sclerosis Patients Josefina Maranzano
Disclosure:
Dr. Maranzano has nothing to disclose.

5:30 PM 371 Neuroinflammatory component of gray matter pathology in multiple sclerosis: a combined 7T and 11C-PBR28 MR-PET imaging study Elena Herranz
Disclosure:
Dr. Herranz has nothing to disclose.

5:30 PM 372 Fingolimod-induced functional neuroplasticity in Multiple Sclerosis Nikolaos Petsas
Disclosure:
Dr. Petsas has received personal compensation for activities with Biogen-Idec Portugal as a speaker, and from Sanofi Genzyme for conference expenses.

Neuroimaging III: MRI Brain Atrophy Measurement Techniques and Analysis in Multiple Sclerosis
Start Time Pub. Title Presenter
5:30 PM 373 Assessment of Brain Atrophy in Multiple Sclerosis Patients in Clinical Routine: A Multi-Center Comparison Study of Radiological and Quantitative Reports Annemie Ribbens
Disclosure:
Dr. Ribbens has nothing to disclose.

5:30 PM 374 Longitudinal brain atrophy measurement techniques in clinical multiple sclerosis practice using magnetic resonance imaging Heidi Beadnall, MD
Disclosure:
Dr. Beadnall has received personal compensation for activities with Biogen, Novartis, Merck and Sanofi-Genzyme as a speaker and advisory board member.

5:30 PM 375 Detecting cerebral atrophy over 5 years in multiple sclerosis: application of a variety of 3T MRI automated segmentation pipelines Renxin Chu
Disclosure:
Dr. Chu has nothing to disclose.

5:30 PM 376 Comparison of Brain Atrophy Measurement Techniques in a Longitudinal Study of Multiple Sclerosis Patients with Frequent MRIs Kunio Nakamura, PhD
Disclosure:
Speaking: Sanofi Genzyme. License fee payment: Biogen. Research support to institution: Biogen, Sanofi Genzyme.

5:30 PM 377 The Impact of Automated Brain Volumetric Analysis on Predicting Brain Atrophy in Patients with Multiple Sclerosis Jia Lin
Disclosure:
Dr. Lin has nothing to disclose.

5:30 PM 378 Segmentation of the cerebral deep gray matter nuclei using 3T and 7T MRI in patients with multiple sclerosis Fawad Yousuf, MD
Disclosure:
Dr. Yousuf has nothing to disclose.

5:30 PM 379 Comparison of whole brain atrophy assessed by proportional vs. registration-based automated pipelines from 3T MRI in multiple sclerosis Christopher Hemond, MD
Disclosure:
Dr. Hemond has nothing to disclose.

5:30 PM 380 Normative Reference Database for Lateral Ventricular Volume Change in Multiple Sclerosis Patients Emmanuele Ghione
Disclosure:
Dr. Ghione has nothing to disclose.

5:30 PM 381 Staging of single MS patients with crossectional aquisition of global, regional and subregional brain atrophy in quantitative MRI Alaleh Raji
Disclosure:
Dr. Raji has received research support from Sanofi Genzyme.

5:30 PM 382 NeuroQuant® in clinical practice: longitudinal observations and platform reliability and performance Allen Nielsen, MD
Disclosure:
Dr. Nielsen has nothing to disclose.

5:30 PM 383 Longitudinal lateral ventricular volume measurement on clinical routine FLAIR scans is clinically relevant even across complete scanner changes Michael Dwyer, MD, PhD
Disclosure:
Dr. Dwyer has received personal compensation for activities with Claret Medical and EMD Serono. Dr. Dwyer has received research support from Novartis.

No Evidence of Disease Activity in Multiple Sclerosis
Start Time Pub. Title Presenter
5:30 PM 384 Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial Jerry Wolinsky, MD, FAAN
Disclosure:
Dr. Wolinsky has received personal compensation for activities with AbbVie, AcademicCME, Alkermes, Bayer HealthCare, Forward Pharma A/S, Novartis, Roche/Genentech, Sanofi Genzyme, Takeda, Teva Pharmaceuticals, and WebMD. Dr. Wolinsky has received royalty payments from University of Texas Health Science Center at Houston.

5:30 PM 385 Prognostic value of early MRI follow-up for no evidence of disease activity (NEDA) after an initial diagnosis of acute disseminated encephalomyelitis (ADEM). Diederik Koelman
Disclosure:
Dr. Koelman has nothing to disclose.

5:30 PM 386 Multimodal EPs predict no evidence of disease activity at two years of first line multiple sclerosis treatment Letizia Leocani, MD
Disclosure:
Dr. Leocani has received personal compensation for activities with Biogen. Dr. Leocani has received research support from Merck Serono and Novartis.

5:30 PM 387 ABSOLUTE AND RELATIVE CHANGE IN NEDA AFTER TREATMENT WITH ORAL DISEASE MODIFYING TREATMENTS IN MS PATIENTS Dimos Dimitrios Mitsikostas, MD, PhD
Disclosure:
Dr. Mitsikostas received personal compensation for activities with Allergan, Amgen, Bayer Schering, Eli Lilly, EMD Serono, Novartis, and Teva as a consultant.

5:30 PM 388 Assessing no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis receiving fingolimod: results from a longitudinal, multicenter, real-world study Bianca Weinstock-Guttman, MD
Disclosure:
Dr. Weinstock-Guttman has received personal compensation for activities with Biogen, Teva Pharmaceuticals, EMD Serono, Genzyme&Sanofi, Novartis and Genentech as a speaker and consultant. Dr. Weinstock-Guttman has received research support from Biogen, Teva Pharmaceuticals, EMD Serono, Genzyme & Sanofi, Novartis, Genentech.

5:30 PM 389 "No evidence of disease activity - cognition" in relapsing-remitting multiple sclerosis: recommendation for an extensive assessment of disease activity Serkan Ozakbas
Disclosure:
Dr. Ozakbas has nothing to disclose.

5:30 PM 390 Early switch to fingolimod for achieving no evidence of multiple sclerosis disease activity: 7-year analysis of data from the TRANSFORMS study Jeffrey Cohen
Disclosure:
Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adams, Celgene. Dr. Cohen has received personal compensation in an editorial capacity for Mult Scler J - ETC.

5:30 PM 391 No Evidence of Disease Activity on Ocrelizumab Treatment in Patients With Early Relapsing Multiple Sclerosis: Pooled Analysis of the Phase III OPERA Studies Eva Havrdova, MD
Disclosure:
Dr. Havrdova has received personal compensation for activities with Biogen, Merck Serono, Novartis, Sanofi-Genzyme, and Teva as an speaker. Dr. Havrdova has received research support from Biogen.

Multiple Sclerosis Diagnosis and Phenotype
Start Time Pub. Title Presenter
5:30 PM 392 The Topographical Model of MS: First Empirical Test of the Recapitulation Hypothesis Benjamin Laitman
Disclosure:
Dr. Laitman has nothing to disclose.

5:30 PM 393 3T FLAIR* MRI improve the differentiation between multiple sclerosis and CNS vasculitis white matter lesions Pietro Maggi, MD, PhD
Disclosure:
Dr. Maggi has nothing to disclose.

5:30 PM 394 A 20-year follow-up study of benign multiple sclerosis in Western Australian cohort Marzena J Fabis-Pedrini, PhD
Disclosure:
Dr. Fabis-Pedrini has nothing to disclose.

5:30 PM 395 Molecular-Based Diagnosis of Multiple Sclerosis and Its Progressive Stages Bibiana Bielekova, MD, FAAN
Disclosure:
Dr. Bielekova received patent royalty payments from National Institutes of Health.

5:30 PM 396 3D Shape and Surface Features Contrast Multiple Sclerosis from Non-Specific White Matter Disease Braeden D. Newton
Disclosure:
Dr. Newton has nothing to disclose.

5:30 PM 397 Number of OCBs in CSF at diagnosis timepoint, - predictor of long term radiological outcome in MS? Björn Evertsson
Disclosure:
Dr. Evertsson has nothing to disclose.

5:30 PM 398 Differentiation of relapsing remitting and progressive courses of multiple sclerosis on MR Spectroscopy using Machine Learning Ziya Eksi
Disclosure:
Dr. Eksi has nothing to disclose.

5:30 PM 399 Disability in the first 10 years of Relapse-onset MS is principally a product of relapses with incomplete recovery Wisam Elmalik, MD
Disclosure:
Dr. Elmalik has nothing to disclose.

5:30 PM 400 MRI characterization of the "central vein sign" in brain white matter lesions of patients with multiple sclerosis but possible "better explanation of the diagnosis" Matteo Grammatico
Disclosure:
Dr. Grammatico has nothing to disclose.

5:30 PM 401 Exploring predictors for the transition from Relapsing to Secondary Progressive Multiple Sclerosis Antje Bischof
Disclosure:
Dr. Bischof has received personal compensation for activities with Biogen as a speaker.

5:30 PM 402 Assessment of clinical definitions of conversion of relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis Camilo Diaz-Cruz, MD
Disclosure:
Dr. Diaz-Cruz has received research support from EMD Serono and Verily.

5:30 PM 403 Axonal degeneration is present in benign multiple sclerosis. Adil Maarouf
Disclosure:
Dr. Maarouf has nothing to disclose.

5:30 PM 404 Revealing underlying differences of NAWM from primary and secondary progressive MS Ines Ramos
Disclosure:
Dr. Ramos has nothing to disclose.

5:30 PM 405 Gadolinium-enhanced 3D-FLAIR MRI: spectrum of pial pathology and imaging pitfalls David Titelbaum, MD
Disclosure:
Dr. Titelbaum has nothing to disclose.

Emerging Science
Start Time Pub. Title Presenter
5:30 PM 406 Delayed-release Dimethyl Fumarate Reduces the Formation of T2 Lesions in Pediatric Patients with Relapsing-Remitting MS: Results From FOCUS, the First Clinical Trial to Evaluate the Neuroradiological Efficacy of an MS Disease-Modifying Therapy in Pediatric Patients Satish Eraly
Disclosure:

5:30 PM 407 Patients Who Received Alemtuzumab in CARE-MS I or II Show a Low Rate of Conversion From Relapsing-Remitting MS to Secondary Progressive MS Through 6 Years Dana Horakova, MD, PhD
Disclosure:

5:30 PM 408 Symptomatic and objective clinical improvement in progressive multiple sclerosis patients treated with autologous Epstein–Barr virus-specific T cell therapy: Interim results of a phase I trial Michael Pender
Disclosure:

Emerging Science
Start Time Pub. Title Presenter
8:30 AM 409 Radiological Evidence for the Long-Term Effect of Fingolimod Treatment in Patients with Relapsing-Remitting Multiple Sclerosis Jeffrey Cohen, MD
Disclosure:
Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Adams, Celgene. Dr. Cohen has received personal compensation in an editorial capacity for Mult Scler J - ETC.

Register Now

Related Courses

Saturday April 21, 2018

7:00 AM-9:00 AM
C1 Mild Cognitive Impairment: Implications for Clinicians Ronald Petersen PhD, MD, FAAN
C2 Functional Neurologic Disorders I: Movement, Seizures, and Speech Disorders Alberto Espay MD, FAAN
C4 Hyperkinetic Movement Disorders: Videodiagnosis and Treatment Steven Frucht MD
7:00 AM-4:00 PM
C6 Neurology MOC Prep Course Nicholas Johnson MD
9:30 AM-11:30 AM
C8 Emergency Neurology: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room Jose Suarez MD
C9 Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies Amanda Peltier MD, MS
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN
C12 Functional Neurologic Disorders II: Life Experiences and Management of Functional Disorders Alberto Espay MD, FAAN
C13 Neuroimaging Biomarkers Across the Dementia Spectrum Liana Apostolova MD, FAAN
C14 Parkinson's Disease Update Melissa Nirenberg MD, PhD, FAAN
C10 More than Medicine: How to Access Home Care, Support Caregivers, and Discuss Complex Situations in Advanced Neurologic Disease Farrah Daly MD, MBA
12:00 PM-1:00 PM
Navigating the Annual Meeting App Carlayne Jackson MD, FAAN
12:00 PM-4:00 PM
C16 Neurophysiologic Intraoperative Monitoring Skills Workshop (Registration Required) Aatif Husain MD
1:30 PM-3:30 PM
C18 Pediatric Neuro-ophthalmology Update Christopher Glisson DO
C20 Evaluation and Management of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia Amanda Peltier MD, MS
C21 Stroke in Young Adults and Women Aneesh Singhal MD, FAAN
C19 The Neurology of Social Behavior Bradford Dickerson MD
C23 Diagnosis and Treatment of Functional Movement Disorders Mark Hallett MD, FAAN
C22 Critical Care Consultations for Neurohospitalists Vanja Douglas MD
4:15 PM-5:30 PM
PL1 Hot Topics Plenary Session

Sunday April 22, 2018

7:00 AM-9:00 AM
C24 Hot Topics and Controversies in Parkinson's Disease Melissa Nirenberg MD, PhD, FAAN
C27 Autism Spectrum Disorders What We Know and Where We Are Going Rujuta Bhatt MD
C30 Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies Michael Shy MD
C31 Treatments for Drug-resistant Epilepsy: Surgery, Devices, and Other Updates Ellen Bubrick MD
C32 Clinicopathological Correlation Session in Dementia David Irwin MD
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
C29 Controversies in Stroke Treatment and Prevention Steven Messe MD, FAAN, FAHA
9:15 AM-12:00 PM
PL2 Presidential Plenary Session
1:00 PM-3:00 PM
C34 Borderlands of Neurology and Internal Medicine: Chalk Talk Martin Samuels MD, MACP, FAAN
C36 Nonmotor Manifestations of Parkinson's Disease I Charles Adler MD, PhD, FAAN
C38 Therapy in Neurology I: Headache and Stroke David Dodick MD, FAAN
C39 Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS Maarten Titulaer MD, PhD
C40 Peripheral Neuropathy II: Diabetic and Inherited Neuropathies Michael Shy MD
C41 Acute and Chronic Clinical Epilepsy Update Explained in 6 Cases Joseph Sirven MD, FAAN
1:00 PM-5:30 PM
C47 Neuromuscular Ultrasound Skills Workshop (Registration Required) Craig Zaidman MD
Genomic Neurology Workshop: Developing Practical Knowledge of Tools and Concepts Through Case Studies Jeffery Vance MD, PhD
3:30 PM-5:30 PM
N1 Neuroscience in the Clinic: Autism Myth Busters Shafali Jeste MD,
Sarah Spence MD,PhD
C50 Nonmotor Manifestations of Parkinson's Disease II Charles Adler MD, PhD, FAAN
C52 Therapy in Neurology II: Epilepsy and Movement Disorders David Dodick MD, FAAN
C53 Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience Maarten Titulaer MD, PhD
C54 Peripheral Neuropathy III: Genetic Testing and Next Generation Sequencing Michael Shy MD
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Monday April 23, 2018

7:00 AM-9:00 AM
C61 Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis Michael Weiss MD, FAAN
C62 Child Neurology I: Pediatric Stroke, MS/Autoimmune Marc Patterson MD, FAAN, FRACP
C63 Clinical Pearls: Learning from Complex Cases Simple Lessons that Apply to Everyday Problems S. Josephson MD, FAAN
C64 Update on Medical Management of Stroke Natalia Rost MD, MPH, FAAN
C66 Cognitive Impairment due to Alzheimer's Disease: Using Old Skills and New Tools for Diagnosis and Treatment David Knopman MD, FAAN
C65 Video EEG: Name That Spell Amy Crepeau MD
C58 Balance and Gait Disorders Bastiaan Bloem MD, PhD
9:15 AM-11:30 AM
PL3 Contemporary Clinical Issues Plenary Session
1:00 PM-3:00 PM
C75 Therapeutic Temperature Modulation in the ICU Stephan Mayer MD
C67 Evaluating Tremor in the Office Vicki Shanker MD
C68 Therapy in Neurology III: Neurological Infectious Diseases and Neuro-ophthalmologic Disorders Madhu Soni MD
C70 Child Neurology II: Epilepsy and Neuromuscular Marc Patterson MD, FAAN, FRACP
C71 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I Jeffrey Gelfand MD, MAS, FAAN
C72 Safe and Appropriate Opioid Prescribing in Neurology Shaheen Lakhan MD, PhD, MEd, FAAN
C73 Clinical Approach to Muscle Disease I: Muscle Disorders and Rhabdomyolysis Tahseen Mozaffar MD, FAAN
C77 Present and Future Biomarkers in Dementia: A Case-based Approach Jonathan Graff-Radford MD
C74 Epilepsy Surgery Update Stephan Schuele MD, FAAN
3:30 PM-5:30 PM
N2 Neuroscience in the Clinic: Antisense Oligonucleotide (ASO) Therapy John Day MD, PhD,
Richard Finkel MD
C85 Child Neurology III: Headache, TBI/Post-concussion Marc Patterson MD, FAAN, FRACP
C84 Therapy in Neurology IV: Neuromuscular Disease and Autoimmune Neurological Disorders Madhu Soni MD
C86 Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II Jeffrey Gelfand MD, MAS, FAAN
C88 Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology Tahseen Mozaffar MD, FAAN
C91 Chronic Traumatic Encephalopathy: Update Andrew Budson MD
C83 Evidence Based Neurology Foresights for Busy Clinicians Andrei Ivashynka MD
C92 Advances in Neurogenetics Matthew Harms MD
C94 Spanish: Update CNS Infections and Tropical Medicine Oscar Del Brutto MD, FAAN
C93 Hot Topics in Education Faculty

Tuesday April 24, 2018

7:00 AM-9:00 AM
C95 Status Epilepticus Stephan Schuele MD, FAAN
C96 Vascular Cognitive Impairment and Dementia: Current Status and Future Larry Goldstein MD, FAAN, FAHA
C97 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
C98 Good Neurology in Challenging Conditions: Lessons from Military Neurology Jeffrey McClean MD, FAAN
C101 Movement Disorders for the General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson's Disease Irene Litvan MD, FAAN
9:15 AM-11:30 AM
PL4 Clinical Trials Plenary Session
1:00 PM-3:00 PM
N3 Neuroscience in the Clinic: Challenges in Genetic Diagnosis in Neurology Guy Rouleau MD, PhD,
Massimo Pandolfo MD, FAAN
C104 Critical Care EEG Monitoring Suzette LaRoche MD, FAAN
C105 Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders Daniel Kaufer MD, FAAN
C107 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
C108 Neurologic Complications in Adults with Down Syndrome Andrea Gropman MD
C110 Continuum Test Your Knowledge: A Multiple-choice Question Review I Steven Lewis MD, FAAN
C113 Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia John Morgan MD, PhD
C114 Cerebrovascular Disease I: Prevention Larry Goldstein MD, FAAN, FAHA
1:00 PM-5:30 PM
C118 EMG Skills Workshop: Basic Ezgi Tiryaki MD, FAAN
3:30 PM-5:30 PM
C119 Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Failed Back Syndrome Ligia Onofrei MD
C129 Disorders of Motor Programming: The Apraxias and Action-Intentional Disorders Chalk Talk Kenneth Heilman MD, FAAN
C121 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD
C122 Child Neurology: A Case-based Approach Elaine Wirrell MD, FAAN
C124 Continuum Test Your Knowledge: A Multiple-choice Question Review II Steven Lewis MD, FAAN
C127 Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics John Morgan MD, PhD
C128 Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke Philip Gorelick MD, MPH, FAAN
C131 Spanish: Update on Science Presented at the Annual Meeting I Alejandro Tobon MD
C130 Introduction to Integrative Neurology Sarah Mulukutla MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C139 Paroxysmal Movement Disorders Kailash Bhatia MD, FAAN
C137 Clinical EEG I: Normal EEG, Normal Variants, and How to Avoid The Common Pitfall of Over-reading Selim Benbadis MD
C134 Neurocognitive Assessment for Neurologists Mario Mendez MD, PhD, FAAN
C135 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
C138 Neurologic Case Studies in Pregnancy Mary O'Neal MD
C140 Integrating Sleep Medicine Concepts into Your Child Neurology Practice Suresh Kotagal MD, FAAN
C141 Mastering EMG Waveform Recognition Skills in Just Two Hours! Devon Rubin MD, FAAN
C132 Higher Cortical Visual Disorders: Case-based Review Sashank Prasad MD
C142 Evaluation and Treatment of Common Spine Disorders J. D. Bartleson MD, FAAN
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C155 Clinical EEG II: Focal, Diffuse, and Epileptiform Abnormalities in Adults Katherine Noe MD, PhD, FAAN
C143 Neurology Update I: Epilepsy, Behavioral Neurology, and Neurologic Infections Ralph Jozefowicz MD, FAAN
C144 Severe TBI: From ICU to Rehabilitation Susanne Muehlschlegel MD,MPH
C145 Non-Alzheimer's Dementia I: Frontotemporal Dementias Gil Rabinovici MD
C146 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
C147 LGBTQI Health in Neurology Holly Hinson MD, MCR
C150 Cerebrovascular Disease III: Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke Philip Gorelick MD, MPH, FAAN
C154 Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System Christopher Gibbons MD, FAAN
1:00 PM-5:30 PM
C158 Clinical Uses of Botulinum Toxin for Dystonia Skills Workshop Diego Torres-Russotto MD, FAAN
3:30 PM-5:30 PM
C169 Clinical EEG III: Neonatal and Pediatric Nicholas Abend MD
C159 Neurology Update II: Movement Disorders, Spine Disorders, and Sleep Disorders Ralph Jozefowicz MD, FAAN
C160 Non-Alzheimer's Dementia II: Lewy Body Dementias and Other Parkinsonian Dementias Gil Rabinovici MD
C161 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD
C165 Cerebrovascular Disease IV: Telestroke Eric Anderson MD, PhD
C167 CNS Toxicities Neeraj Kumar MD
C168 Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System Christopher Gibbons MD, FAAN
C170 Spanish: Update on Epilepsy Therapy Andres Kanner MD, FAAN

Thursday April 26, 2018

7:00 AM-9:00 AM
C178 Clinical EMG I: Principles and Practice of NCS and Needle EMG Ruple Laughlin MD, FAAN
C171 Clinical Epilepsy I: Basics Tracey Milligan MD, FAAN
C173 Rehabilitation in Neurology Marc Slutzky MD, PhD
C174 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
C176 The Dystonia: Diagnosis, Treatment and Update on Etiologies Rachel Saunders-Pullman MD
C179 Principles of Genomic Medicine: Clinical Exome Sequencing in Neurologic Disease Wayne Grody MD, PhD
C180 Preventive Neurology: How Neurologists Can Improve Outcomes That Matter to Patients Joel Salinas MD
9:15 AM-11:30 AM
PL6 Controversies in Neurology Plenary Session
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN
C192 Assessment of Rapidly Progressive Dementias I: Overview, Prion Diseases, and Neurodegenerative Rapidly Progressive Dementia Michael Geschwind MD, PhD
C191 Clinical EMG II: Neuromuscular Junction Testing and Quantitative EMG Mark Bromberg MD, PhD, FAAN
C181 Clinical Epilepsy II: Considerations Across the Age Span Pediatrics, Pregnancy, and Elderly Barbara Jobst MD, FAAN
C183 Behavioral Neurology I: Network Anatomy of Behavior and Language Maria Gorno Tempini MD, PhD
C184 Neurology Update III: Neuromuscular, Headache, and Stroke Adam Quick MD
C185 Myelopathies I: Recognizing and Evaluating Myelopathic Patients for Inflammatory and Vascular Causes Benjamin Greenberg MD, FAAN
C186 Cerebellar and Afferent Ataxias: Diagnosis and Management Massimo Pandolfo MD, FAAN
C187 Neuroimaging for the General Neurologist I: Spine and Peripheral Nerve Joshua Klein MD, PhD, FANA, FAAN
C194 Spanish: Update on Stroke Therapy Carlos Kase MD, FAAN, FAHA
3:30 PM-5:30 PM
C207 Assessment of Rapidly Progressive Dementias II: Autoimmune Encephalopathies and Infections Presenting as Rapidly Progressive Dementia Michael Geschwind MD, PhD
C205 Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches Mark Bromberg MD, PhD, FAAN
C198 Neurology Update IV: Multiple Sclerosis, Neuro-ophthalmology, and Autoimmune Encephalopathies Adam Quick MD
C196 Clinical Epilepsy III: Advanced (Status, Beyond AED, Video EEG) Tobias Loddenkemper MD
C197 Behavioral Neurology II: Memory and Attention Maria Gorno Tempini MD, PhD
C199 Myelopathies II: Approaches to Rehabilitation and Psychosocial Challenges Benjamin Greenberg MD, FAAN
C201 Neuroimaging for the General Neurologist II: Spine and Peripheral Nerve Joshua Klein MD, PhD, FANA, FAAN
C202 Endovascular Treatment of Acute Stroke and Cerebrovascular Disease Dileep Yavagal MD, FAAN
C208 Clinical Usefulness of Botulinum Toxin for Spasticity Skills Workshop Allison Brashear MD, MBA, FAAN
C206 Mitochondrial Disorders in Neurology Michio Hirano MD, FAAN
6:30 PM-9:30 PM
C209 Case Studies: Unusual Diagnostic and Management of Cases in Neuromuscular Disease Anne Connolly MD, FAAN
C211 Case Studies: Test Your Knowledge: A Case-based Approach to Neuroimaging Joshua Klein MD, PhD, FANA, FAAN
C212 Case Studies: Unusual Movement Disorders Kailash Bhatia MD, FAAN
C214 Case Studies in Behavioral Neurology: Focus on Frontotemporal Degeneration Daniel Kaufer MD, FAAN

Friday April 27, 2018

7:00 AM-9:00 AM
C218 The Early-Onset Dementias Mario Mendez MD, PhD, FAAN
C215 Neuroendocrine Update: Nuts and Bolts of What You Need to Know Alison Pack MD
C216 Current Management of Incidental and Asymptomatic Cerebrovascular Lesions Seemant Chaturvedi MD, FAAN, FAHA
C219 Drugs and Toxin-induced Neurologic Emergencies Sara Hocker MD
C221 Therapy of Movement Disorders: A Case-based Approach David Riley MD
C222 The Burden of Epilepsy: Managing Comorbidities and Quality of Life Gregory Cascino MD, FAAN
9:15 AM-11:30 AM
PL7 Neurology Year in Review Plenary Session
1:00 PM-3:00 PM
C223 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN
C224 Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia Laura Tormoehlen MD
C226 Behavioral Neurology: A Case-based Approach A. Barrett MD, FAAN
C227 Neuroimaging for the General Neurologist I: Brain Jennifer McVige MD
C228 Deep Brain Stimulation I: Basic Principles and Programming in Movement Disorders Jill Ostrem MD
C229 Neurologic Complications of Medical and Surgical Therapies Sara Hocker MD
C232 Spanish: Update on Science Presented at the Annual Meeting II Jose Cavazos MD,PhD, FAAN
1:00 PM-5:00 PM
C233 Epilepsy Skills Workshop: Focus on Treatment William Tatum DO, FAAN
3:30 PM-5:30 PM
C234 Neck Pain, Cervical Spinal Stenosis, Cervical Radiculopathy, and Cervical Spondylotic Myelopathy John Engstrom MD, FAAN
C235 Neuromuscular Junction Disorders II: Toxins, Lambert-Eaton Syndrome and Less Common Disorders of Neuromuscular Transmission Laura Tormoehlen MD
C236 Neurologic Complications of Medical Disease Sara Hocker MD
C237 Memory Disorders: A Case-based Approach David Wolk MD
C239 Neuroimaging for the General Neurologist II: Brain Jennifer McVige MD
C240 Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders Jill Ostrem MD

MEMBER LOG IN

Forgot Password?